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INTRODUCTION 
 
Rotaviral gastroenteritis is one of the leading causes of mortality and morbidity in 
Indian children below 5 years of age. India spends about 2 to 3.4 billion rupees 
annually on the treatment of these cases (1). One in approximately every 260 children 
below five years of age die of rotavirus diarrhea every year (2).  
Faeco oral route is the most important mode of transmission and hence improvement 
in sanitation and general hygiene should ideally prevent transmission. However, even 
in the developed countries, this could not be achieved. It is difficult to prevent feco-
orally transmitted diseases in developing countries without multiple preventive 
measures, including vaccination. The World Health Organization (WHO) has 
recommended incorporation of vaccines against rotavirus diarrhea in the national 
immunization schedules of  developing countries with high diarrheal mortality (3). 
Though vaccines are available, they have to be in a reasonable price range to be 
affordable for the poorer countries which have the majority of the mortality and severe 
disease burden. To cater to this need in India, various indigenous vaccines are being 
developed. 
Rotavirus is a double stranded RNA virus belonging to the family Reoviridae. The 
genome is segmented. The virus is a triple layered particle with outer, middle and 
inner layers. Different serogroups are identified based on the antigenic specificity of 
the middle layer of the virus and electrophoretic mobility of the 11 RNA segments of 
the viral genome. Out of the seven different serogroups (A – G) identified, groups  A, 
B and C are associated with humans and group A viruses are most commonly 
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associated with severe life threatening  disease worldwide (1). Among the serogroups, 
there are genotypes which are designated G and P types based on the antigenic 
determinants of the outer layer. Distribution of the genotypes varies from place to 
place and more than one genotype may exist in a given geographical region.  
Gastroenteritis with its causes, pathophysiology and clinical features is a well defined 
entity. The choice of variables in objectively defining the severity of gastroenteritis 
are varied. Defining severity objectively helps in assessment of the effect of 
therapeutic and preventive intervention. In assessing severe disease, a number of 
scoring systems have been developed, based on objective signs and symptoms 
reported by mothers. The most widely used scoring system for clinical assessment of 
severity is the 20 point Vesikari scoring system (4) with seven different components 
determining if an individual has mild, moderate, severe or very severe gastroenteritis.  
Rapid development of molecular techniques helped not only in detection but also in 
quantitation of the virus. Virus quantitation in stool is a marker for viral replication 
since gut is the primary site of viral replication. Real-time polymerase chain reaction 
(RT-PCR) is a simple, very sensitive and less time consuming test in comparison to 
conventional PCR assays in detecting very small amounts of nucleic acid with less 
chance for cross contamination. It enables us to view the increase in the amount of 
DNA as it is amplified in real time. It has been estimated that real-time PCR resulted 
in 186% increase in detection of the virus as compared to electron microscopy (5).  
Quantitation using real time polymerase chain reaction, has helped in studying the 
associations of viral load with various aspects of pathogenesis and outcome of 
infection. In a previous study on rotavirus infection and gastroenteritis, it was found 
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that children with more severe diarrhea had greater viral loads (6). Although any gene 
of the virus could be amplified for quantitation, generally if the purpose is to 
distinguish between related viruses, a variable region of the genome is used and if the 
purpose is to quantify the amount of virus, a conserved region is used for 
amplification. Among the relatively conserved viral genes, VP6 is a suitable target for 
amplification and encodes the protein used for grouping rotaviruses. VP6 is a 
structural protein of rotavirus which forms the middle coat of the triple layered 
particle. It is highly antigenic and is employed in several commercial kits available for 
detection of rotavirus through enzyme immune assays. 
This study estimated the viral load in stool samples from children with gastroenteritis 
in Vellore by quantitative real time reverse transcriptase PCR of the VP6 gene using 
Taqman probes. 
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AIM OF THE STUDY 
To study the correlation between Group A rotavirus load and severity of 
gastroenteritis. 
OBJECTIVES OF THE STUDY 
To correlate viral load by real-time PCR in children with mild, moderate and severe 
rotavirus gastroenteritis assessed by the 20 point Vesikari scoring for rotavirus 
diarrhea. 
Hypothesis 
Clinical severity of rotavirus gastroenteritis will correlate with the amount of virus 
excreted.  
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JUSTIFICATION FOR THE STUDY 
 
The study was conducted to examine viral excretion from children with rotaviral 
gastroenteritis in stool samples with defined Vesikari scores. Vaccines are being 
developed indigenously and there will be a need to test them for their ability to 
prevent severe rotavirus diarrhoea. In order to provide an additional capacity to test 
severe disease, we intended to estimate the range of viral excretion in children with 
Vesikari scores for mild (score 1-5), moderate (score 6-10), severe (score 11-15) and 
if possible, very severe disease (score 16-20). With the ongoing clinical trials on 
vaccines, estimation of viral load in stools excreted will be an important tool in 
studying vaccine efficacy.  
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REVIEW OF LITERATURE 
 
1. ROTAVIRUS DISEASE BURDEN 
1.1 Global scenario 
Globally, diarrhoea is the second leading cause of death among children under five 
years of age (7,8). One of every nine deaths in this age group is because of diarrhea 
(7). Worldwide statistics in 2008 reveal that approximately 4,53,000 deaths due to 
diarrhea in the under five age group are because of rotavirus infection i.e. about 37 
percent of all diarrheal deaths and five percent of all deaths in the <5year age group 
are because of rotavirus diarrhea (2). When categorised into mild, moderate and 
severe diarrhea based on the care to be given, i.e. home care, hospital/ clinic visit and 
hospital admission respectively, rotavirus diarrhea has been estimated to result in 
approximately 111 million episodes requiring home care, 25 million cases requiring 
out-patient visits to a hospital and 2 million cases requiring hospitalization in the 
under five age category (9). 
By the time children reach 5 years of age, almost all of them would have an episode of 
rotaviral diarrhea. One in five children will visit the out-patient clinic and one in 60 
children will be admitted to a hospital (9). About 98% of rotavirus diarrheal deaths 
occur in the developing countries. The five major countries contributing to  more than 
half of rotavirus diarrheal deaths are Ethiopia, Democratic Republic of Congo, 
Nigeria, India and Pakistan (10). Nearly  95% of all children will have evidence of 
prior infection (11). 
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Figure 1. Causes of death in children in the <5 year age group 
 
1.2 Disease burden: India 
An estimate of disease burden revealed that about 122,000-153,000 rotavirus diarrhea 
deaths are from India (1). In other words, India contributes to over 20% of the 
rotavirus diarrheal deaths globally (12). In addition, 457,000–884,000 hospital 
admissions, and over 2 million out-patient consultations in children <5 years of age 
occur annually in India because of rotaviral diarrhea (1). This poses a heavy economic 
burden on a developing nation. 
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1.3 Economic burden 
The total medical costs can be broadly divided into direct and indirect costs. Direct 
costs are direct medical expenses incurred which pertain to hospitalization and 
treatment. Direct non-medical costs pertain to transportation to and from the hospital, 
amount spent by the family to stay with the sick child at the hospital, etc. Indirect 
costs include loss of wages incurred by the parents,etc. The expenditure incurred 
differs with the level of care i.e. primary, secondary or tertiary level hospitals.  
 
Table 1. Economic burden of rotaviral diarrhea in children < 5 years of age in 
Vellore, India (13) 
Level of care Direct medical cost per 
hospitalization 
Direct non medical costs per 
hospitalization 
Primary Rs. 1833.28  Rs.  45.72 
Secondary Rs.  4289.56 Rs.  332.46 
Tertiary Rs.  3530.81 Rs.  46.20 
 
Thus the burden of direct medical costs due to rotaviral gastroenteritis in India in 
children <5 years of age ranges from Rs. 1.8 to 3.2 billion annually. The indirect costs 
account for a 64 million rupees in the outpatient visit setting (1). India spends Rs. 
71.93 – 126.17 per child per year for treating rotaviral gastroenteritis (1). 
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2. ROTAVIRUS:   HISTORY 
In 1963, Adams and Kraft, using the electron microscope described murine rotavirus 
as the causative agent of epizoonotic diarrhea in infant mice (EDIM) (14). Following 
this, rotaviruses were also isolated from many other animals with gastroenteritis.  
In 1973, viral particles were seen by electron microscopy of biopsies from duodenal 
specimens from children with gastroenteritis. They were about 70nm in diameter (15). 
Thereafter, they were observed in stool samples of children with diarrhea (16–18). 
Because of their morphological appearance, they were designated Rotaviruses (in 
Latin where „rota‟ means „wheel‟). They were soon identified as causative agents in 
gastroenteritis in children worldwide. 
 
2.1.  REOVIRIDAE FAMILY 
Rotavirus belongs to Reoviridae family. The Reoviridae family comprises of nine 
genera. The viruses exhibit a wide host range, which include plants, invertebrates and 
vertebrate hosts. The most common genera that are important in human diseases are 
Orthoreovirus, Orbivirus, Rotavirus, Coltivirus, and the Seadornavirus. Their genome 
is made up of double stranded RNA surrounded by a non-enveloped capsid. The size 
of the virions is approximately 60 to 80 nm and the RNA exists in 10 to 12 segments, 
which can reassort giving rise to novel viruses. 
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2.2. STRUCTURE OF ROTAVIRUS 
The virus is 70 nm in size excluding the spikes. Unique features of this virus are a 
segmented genome and the presence of RNA dependent RNA polymerase. The 
protein capsid is icosahedral in symmetry and is comprised of three layers; an outer, 
intermediate and an inner layer. Spikes made of protein project from the surface of the 
outer layer. With the spikes, it is about 100 nm in size. The RNA is double stranded 
and exists as 11 segments. The virus is a triple layered particle (TLP). The three layers 
consist of an inner layer, a middle coat and an outer capsid. These three layers enclose 
the tightly packed segmented double stranded RNA along with the VP1 polymerase 
and VP3 capping enzyme complexes. Each gene segment has atleast one open reading 
frame and encode the structural and non structural proteins. All gene segments except 
segment 11 are monocistronic. The innermost layer is a protein shell made up of 120 
copies of VP2 forming an icosahedral lattice.  
The middle layer consists of 780 copies of VP6. This layer exists as trimeric pillars in 
an icosahedral lattice. Though it is not exposed on the viral surface, VP6 is the main 
target for the majority of antibodies elicited in rotavirus infection. Its function is to 
coordinate the entry into the cell through interactions with the outer proteins VP7 and 
VP4. The outer most layer is a thin glycoprotein layer formed by 780 copies of VP7.  
Sixty spikes made up of VP4 project from the surface of the outer layer of the virion. 
Aqueous pores perforate the middle and outer layers. The structural proteins of the 
outer layer, VP4 and VP7 elicit neutralizing antibodies. VP4 gets cleaved into VP8* 
and VP5* which enhances cell infectivity and penetration into the host cell. VP7 
mediates calcium dependant uncoating of the virus and along with VP4 (19), help in 
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translocating the double layered sub viral particle across the host cell membrane into 
the cytoplasm (20). 
The virus is hardy and is not easily inactivated by treatment with various organic and 
inorganic chemicals like ether, fluorocarbons, and chlorine at concentrations used for 
sewage effluent and potable water treatment. They survive for weeks in drinking and 
recreational waters. They have the ability to retain their infectivity for several days on 
inanimate surfaces under favourable conditions of humidity (21). They are inactivated 
by antiseptics containing  relatively higher alcohol concentrations(>40%), >20000 
ppm of  free chlorine or iodophores with >10000 ppm iodine and calcium chelators 
(22). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Structure of Rotavirus 
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2.3.  PATHOGENESIS 
The most common route of transmission of rotavirus is the faeco-oral route. The 
manifestation of clinical infection depend on the viral and host factors. The single 
most important host factor affecting the outcome of infection is the age of the 
individual. Thus early neonatal period is spared owing to the transplacentally acquired 
maternal antibodies. Adults rarely present with life threatening diarrhea unless it is 
caused by an unusual strain or with a very high infective dose.  
Virus factors involve the proteins encoded by various genes. The genes that are shown 
to be associated with virulence are 3, 4, 5, 9 and 10. Gene 10 encodes the non 
structural protein 4 which functions as an enterotoxin. It also regulates viral 
replication and calcium balance in the enterocyte environment. As compared to 
bacterial diarrhea, virus induced diarrhea shows little inflammation. Once ingested, 
the virus not destroyed by the stomach acidity gets attached to the small intestinal 
epithelial cells. An interaction between the virus and a series of sialylated and non 
sialylated receptor molecules on the host surface brings about binding of the virus to 
the host cell. Studies in animal models show that intestinal villous epithelium is the 
site of attachment whereas the crypt epithelium is relatively spared (23).  
The pathophysiology is multi-factorial. The postulated mechanisms of pathogenesis 
involve a malabsorption component resulting from damage to the absorptive intestinal 
villi caused by the virus. There is also a down regulation of absorptive enzymes 
produced by the enterocyte. Rotavirus causes an increase in intracellular calcium thus 
disturbing the intracellular homeostasis. NSP4 plays a key role in the increase in 
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intracellular calcium ions. It causes the release of Ca2+ from the storage sites like the 
endoplasmic reticulum. NSP4 from prior infected cells after binding to specific 
receptors on adjacent enterocytes result in phospholipase C- inositol 1,3,5 triphosphate 
mediated cascade of events ultimately causing an increase in intracellular Ca2+.  
NSP4 can directly act on crypt cells or directly stimulate enteric nervous system, 
which increases Ca2+ in the cells. When NSP4 acts directly on the crypt cell, there is 
activation of Cl
-
 transporter contributing to secretory diarrhea because there is a 
concomitant increase in water secretion. Microvillar cytoskeletal made up of Ca2+ 
sensitive F-actin, villin and tubulin proteins undergoes disruption. NSP4 also acts on 
the tight junctions, which maintain epithelial barrier decreasing the intracellular 
resistance and cause paracellular leakage. The degree of damage to the mucosa 
correlates with the severity of diarrhea (24).  
The other mechanism involves an alteration in Na+/K+ equilibrium as a result of 
increased plasma membrane permeability. There is an increased intracellular Na+ and 
a decreased intracellular K+ (25). This imbalance may cause decreased NaCl 
absorption and solute absorption, which takes place alongside Na+ and hence results 
in water secretion into the lumen of the gut.  
Sodium glucose transport protein 1 (SGLT1) which is responsible for sodium 
reabsorption by the enterocytes is competitively inhibited by NSP4 (26). The enteric 
nervous system is situated immediately beneath the villous epithelium receives stimuli 
from the damaged cells. Also the prostaglandins and the chemokines released during 
epithelial damage stimulate the enteric nervous system which in turn trigger the crypt 
cells to pour out the secretions into the gut lumen. 
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Immunofluorescent staining and light microscopic examination of duodenal biopsy 
specimens from children presenting with severe diarrhea showed patchy rotavirus 
antigen distribution over the villous epithelium and short blunt villi with crypt 
hypertrophy respectively (24,27). 
 
 
 
 
.  
 
 
 
 
 
 
Figure 3. Pathogenesis of rotavirus diarrhea 
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2.4. IMMUNITY IN ROTAVIRAL INFECTIONS 
Protective immunity is mediated by both the cellular and humoral immune system. 
Serological response to the first infection is believed to be homotypic i.e. directed 
towards specific viral proteins. The subsequent infections elicit a heterotypic 
serological response which is broader (28). In the case of most immunocompromised 
patients, severe diarrhea is rarely a consequence of natural infection but viral shedding 
takes place over a prolonged duration.  
Severe diarrhea is however seen in severely immunocompromised individuals (i.e. 
congenital immunodeficiency states, solid organ or bone marrow transplant patients) 
(29). Studies have shown that in children, soon after natural infection, rotavirus 
specific serum IgA correlates with intestinal IgA levels and it can be used as a 
correlate for protection, and in vaccine trials, circulating IgA antibody levels in serum 
have been considered the best marker for vaccine take (30). 
Rotavirus antigenemia was observed in children with rotavirus diarrhea and this 
showed correlation with viral load detected in the stool samples. This however did not 
translate into any increase in extra intestinal manifestations of the infection (31). 
Viremia was seen in 90% of antigenemic children in a study. The presence of viremia 
can be explanatory of the extra intestinal manifestations of the infection (32).  
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3. CLINICAL FEATURES 
The clinical spectrum is varied and ranges from asymptomatic subclinical infection to 
severe life threatening diarrhea resulting in death. The incubation period lasts for 1 – 3 
days and symptoms that follow may be of abrupt onset. There are however no striking 
clinical or epidemiological features which can differentiate a child with rotaviral 
diarrhea from a child with diarrhea attributable to any other etiology. 
Infections in  neonates may be asymptomatic because of the presence of circulating 
maternal antibodies (33,34). In addition, the immature alimentary tract and also the 
phenomeneon of reassortment occurring in the rotavirus genome giving rise to unique 
strains with a possibly different virulence mechanisms may be responsible for the 
asymptomatic nature of most of the neonatal infections. It was also noticed that the 
first episodes of rotaviral infection, past the neonatal period (around 3 to 24 months of 
age) may present with more vomiting than watery diarrhea, along with fever. Even 
beyond this period, vomiting frequently precedes diarrheal onset and may persist for 2 
to 3 days. About a third of patients present with fever. Loose and watery stools are 
typical leading to life-threatening dehydration. The dehydration associated with this 
virus is comparatively more severe than that associated with other common gut 
pathogens(35,36). Diarrhea may continue for 4 to 5 days. Dehydration and the 
resulting electrolyte imbalance leads to cardiovascular failure which is the most 
common cause of death (37). Virus can be detected in infected stools using antigenic 
tests for about 4 to 10 days after the onset of symptoms. Using more sensitive 
methods like reverse transcriptase PCR, the detection can extend to 57 days though 
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the child may not be shedding infectious particles at this point (38). Usually there are 
no RBC or leukocytes in the stool (39). 
In children with immunocompromised states, rotavirus infection manifests as chronic 
diarrhea. Neurological symptoms and the subsequent detection of rotavirus in cerebro 
spinal fluid of children have been reported. Various other conditions like aseptic 
meningitis, otitis media and respiratory illnesses which are extra intestinal infections 
have also been reported. Detection of rotavirus antigenemia and viremia in children 
with gastroenteritis is in support of extra intestinal manifestations. The virus has also 
been seen in a variety of conditions like sudden infant death syndrome, 
intussusception and necrotizing enterocolitis, but these findings may be co-incidental 
and not causal (40,41). 
4. EPIDEMIOLOGY 
Six to twelve months of age is the most vulnerable period for severe gastroenteritis 
(42). The age at which severe gastroenteritis usually happens is proportional to the 
waning of maternally derived antibodies, the maturation of the child‟s GI tract and the 
active acquisition of immunity due to natural infection (43). Though the rate of 
occurrence of rotaviral infection is similar in both developed and developing 
countries, mortality is higher in the latter. Malnutrition, lack of access to timely 
medical care, coinfections with other intestinal pathogens may be some of the 
contributing factors (44). The hardy nature of the virus, its relatively high 
concentrations of 10
11
 particles/mL in stool (45) and low minimum infective dose of 
10 focus forming units (46) are also responsible for the high incidence rates. The peak 
incidence in temperate regions is in the cooler months (47). Cooler and drier months 
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are preferred in the tropical areas though there is no clear demarcation in the seasonal 
appearance in the tropics. The drier climate may be preferred for its transmission 
because of lower relative humidity which inactivates the virus (21).  
 
Figure 4. Mortality due to rotavirus in the <5 year age group 
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4.1 SEROTYPES/ GENOTYPES 
There is a high level of antigenic and genomic variability in circulating human 
rotaviruses. Both antigenic determinants and genomic information have been used as 
the basis for classification. Serogroup is the broadest unit of classification, and is 
based on the VP6 protein. Seven groups (A-G) are identified, among which group A 
rotaviruses are found to be the commonest, causing life threatening diarrhea in 
children all over the world. The determination of serogroups and these subgroups was 
carried out by using hyperimmunized serum from animals (32). The VP6 antigen can 
be detected by serological tests like immunofluorescence, enzyme immunoassays and 
methods like immune electron microscopy. Genetic reassortment can take place 
between rotaviruses of the same group but does not occur among different serogroups. 
Groups A, B, and C rotaviruses are seen in humans and animals. Groups D, E, F, and 
G have been reported only in animals so far. Group A rotaviruses are implicated in 
endemic diarrhea of children. Group B and group C infect all age groups. The adult 
diarrhea rotavirus (ADRV) belongs to Group B and it was responsible for  massive 
outbreaks of adult gastroenteritis in China (49). Group C is associated with mild 
diarrhea in both adults and children (50,51). 
Serogroup A is further divided into various subgroups. They are subgroups I, II, I+II, 
and non-I non-II based on monoclonal antibody recognition of VP6 antigenic 
determinants (52). The initial serological classification within group Agave a binomial 
nomenclature comprising of a „G‟ serotype and a „P‟ serotype for each virus strain. 
Thetwo proteins, VP7 and VP4, of the outer layer and the spikes, respectively, induce 
antibody responses which are neutralizing and the genetic variability involved in 
 
 
20 
 
encoding them is the basis for G and P type classification (53). Around 14 G serotypes 
(G1 to G14) and atleast 20 P serotypes (P[1] to P[20]) are identified so far and of 
these, 10 G types and about 5 P types are found in humans infected with rotaviruses 
(53).  
In the case of G type, there is a one to one correspondence between the protein and 
gene, such that serotypes, based on monoclonal antibodies, and genotypes have the 
same nomenclature. This is however not the case with P serotypes where there are a 
lot of cross reactions within the P serotypes, and a P serotype can include more than a 
single genotype.  
Rotavirus strains may exhibit a degree of confinement to a particular geographic 
region or variations with climatic conditions. Factors like genetic reassortment 
between animal and human strains, antigenic drift and introduction of animal 
rotaviruses into the circulating pool of human strains ensure a continuous 
phenomenon of genetic diversity. Hence surveillance becomes imperative in 
determining whether new strains are emerging (54). Several G and P types may be 
circulating in a given diarrheal season. Though there are dominant G and P types with 
geographical confinement, they may be replaced by other strains during a particular 
rotaviral gastroenteritis season (55). Till 1990, the four most common combinations of 
G and P types seen were G1P[8], G2P[4], G3P[8] and G4P[8]. With increased strain 
surveillance, new GP combinations are being found. Currently, the most commonly 
occurring G serotypes are G1 to G4 and G9. The commonest P genotypes are P[4], 
P[6] and P[8] and their corresponding serotypes are 1B, 2A and 1A respectively (56). 
The five most prevalent GP combinations are G1P[8], G2P[4], G3P[8], G4P[8] and 
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G9P[8]. Uncommon strains are also found. Regional serotypes of importance are 
G8P[6] in Africa and G5P[8] in Brazil (48). The G9 strains were first identified in 
children with gastroenteritis in Philadelphia. There are some reports of increased 
severity of gastroenteritis in Latin American countries (57), and children <6 years 
showed increased risk of infection by the new strain (58). Currently G9P8 strains are 
one of the most commonly circulating strains worldwide. Children can have multiple 
episodes of diarrhea caused by different G and P types. The protective efficacy of the 
prior natural rotavirus infection over the subsequent infections ranged from 46% to 
100%. Generally it is thought that the initial infections conferred homotypic protection 
which later broadened to a heterotypic protection. A more recent study conducted by 
Kang et al, where 373 children were followed up from birth for a three year period 
showed that although there was protection, there was no evidence of homotypic 
protection alone offered by the initial  infections (59).  
4.2 GENOTYPES IN INDIA 
Strains belonging to different genotypes are reported from different parts of the 
country. G1, G2, G4, G9 and G12 are among the commonest VP7 genotypes and P[4], 
P[6], P[8] and P[11] are the common P types reported from all over India. With the 
introduction of molecular biology based typing methods, detection of so far 
untypeable strains is being done and thus the unusual strains are increasingly being 
detected. Many of them are believed to be of animal origin or reassortants between 
animal and human strains because of their identity with the corresponding genes in the 
rotaviruses infecting animals.  
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G6 strain and G8 strain showed more than 95% identity with VP7 gene of the bovine 
rotavirus strains. The G6 strain was described from Pune (60) and G8 from Vellore 
and Mysore (61,62). The VP7 gene of G3P[8] shares 100% identity with the VP7 of 
simian rotaviruses and the P[8] component has 99% identity with the P[8] of human 
rotaviruses. This was described among the tribal residents of Western India (63). 
G9P[19] is a porcine–human reassortant and is described from Manipur (64). Another 
genotype which is a bovine – human  reassortant is the G10P[11] genotype described 
from Vellore (65). G12 strains which were first identified in Philippines were 
increasingly reported from India. The G12 genotype is seen in combination with many 
P types. Among hospitalized children, data from Vellore during the period 2002- 2005 
reveal that the most predominant VP7 types were G1 followed by G9 and then G2 
(65). A reversal of the above order was observed in studies conducted in the same 
region during 2005-2007 where G2 was the most common G type followed by G9 and 
then G1. Other genotypes like G3 and G4 which are among the commonest types 
found worldwide were not reported. 
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Figure 5. Global distribution of G and P types from five continents between 1989 
and 2004  (Rev.Med. Virol. 2005) 
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5. LABORATORY DIAGNOSIS OF ROTAVIRUS 
 
The different techniques to detect rotavirus in the laboratory are i) Virus isolation 
using cell culture techniques, ii) Electron microscopy, iii Serological methods to 
detect the antigen, including Enzyme immunoassay (EIA), Latex agglutination, 
Immunochromatography and iv) Nucleic acid detection.  
5.1. Cell culture techniques for virus isolation 
Virus isolation can be performed on rhesus monkey kidney cell lines (MA104, LLC-
MK2 cell line), African green monkey kidney cell lines (BSC1, CV1) and Madin 
Darby bovine kidney cell line. After an incubation period of 18 hours, the cell line is 
examined for cytopathic effect. 
5.2. Electron Microscopy 
It demands well trained personnel with technical expertise and is a very expensive 
instrument. Moreover, the distinction between the various serogroups cannot be made 
based on electron microscopy. A minimum number of viral particles for detection by 
electron microscopy is 10
7 
viral particles/ml of stool (17).  
5.3. Serological tests for Antigen detection 
The most common methods in serological detection employ antibodies specific for 
rotavirus antigens. The captured antigen is detected in a colorimetric reaction where a 
second rotavirus specific antibody attached to a detector enzyme is employed. The 
result in terms of optical density values is recorded by the standard plate reader.  
Three commercial kits are recommended for surveillance in the manual on rotavirus 
detection and characterization by the WHO are Premier
TM
Rotaclone (Meridian 
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Biosciences; Cincinnati), ProSpecT™ (Oxoid) and RIDASCREEN® (R-biopharm, 
Darmstadt, Germany).  
Table 2. Performance of commercially available EIA kits for rotavirus detection 
Study ELISA kit   Reference test Sensitivity Specificity 
R Gautam et 
al., 2013(66) 
Rotaclone 
ProSpecT 
Ridascreen 
Reverse 
transcription 
PCR 
76.8%, 75% 
and 82.1% 
respectively 
100% 
Bodo RE et al., 
2001(67) 
1.Ridascreen 
2.Pathfinder 
rotavirus 
Electron 
microscopy 
100% 99.73% and 
79.1% 
respectively 
Morinet F et 
al.,1984(68) 
Rotazyme 
Enzygnost 
-Relative 
sensitivity- 
89% and 98% 
respectively 
--- 
JL Cromien et 
al., 1987(69) 
Rotazyme EIA 
Rotazyme II 
EIA on 
MA104 cell 
culture 
supernatants 
using the same 
kits 
100% 100% and 90% 
respectively 
Dennehy PH et 
al.,1988(70) 
1.Rotaclone 
2.Pathfinder 
rotavirus 
RNA-PAGE 100% 100% and 98% 
respectively 
 
 
5.4. Latex agglutination methods 
Latex particles are coated with the antibody specific for rotavirus antigen and if the 
antigen is present in the fecal specimen, there would be agglutination of the latex 
particles. This can be performed on a glass slide and visualised by the unaided eye or 
by use of a hand lens. It was thought that this test was faster and cost effective and 
could be performed in the paediatric wards. Initial evaluation of Rotalex, a latex 
agglutination kit by Orion diagnostics, Helsinki Finland, showed low sensitivity and 
specificity when compared to enzyme immunoassay and electron microscopy (71).  
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5.5. Immunochromatography 
In resource poor settings, immunochromatography may help overcome the barriers in 
detection and studying the epidemiology of rotavirus diarrhea. Though the sensitivity 
and the specificity obtained using some kits was comparable to that of enzyme 
immunoassay, latex agglutination in some studies(72–74), others have reported 
discordant results (75,76). 
5.6. Nucleic acid detection methods 
5.6.1. RNA Polyacrylamide gel electrophoresis 
Large amount of viral particles are shed from stools in children with gastroenteritis 
and the nuclear segments can be visualised after extracting from the virus and running 
it electrophoretically on polyacrylamide gel after staining with either silver nitrate or 
ethidium bromide. Groups A, B and C are the human rotavirus groups and these have 
distinct bands corresponding to gene segment distribution after electrophoresis. Since 
this method detects both the presence of rotavirus and its serogroup, polyacrylamide 
gel electrophoresis (PAGE), has been used for Group A rotavirus surveillance.  
The RNA which is extracted from Group A rotavirus can be categorised into four 
classes based on the size; large, medium, small and smallest segments. They also 
occur in „short‟ and „long‟ electropherotypes. This procedure is labour intensive and 
needs a trained technologist. The sample is considered positive for Group A rotavirus 
if the 11 segments of double stranded RNA are visible and correspond to the group A 
rotavirus control.  
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Figure 6. PAGE gel showing differences in segment migration configuration of 
Group A, B and C Rotavirus 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6.2. Reverse transcription PCR 
Reverse transcriptase PCR helps in improved identification of viral shedding when 
compared to enzyme immunoassay, latex agglutination or immunochromatography 
tests (77,78). Viral nucleic acid can be detected 2 to 7 days longer than when detected 
using the enzyme immunoassay (77). RT-PCR can detect and identify the G and P 
types by using primers which are specific for the VP7 and VP4 genes. The PCR 
products which are obtained are genotype specific and can be detected after running 
electrophoretically on agarose gel. Reverse transcriptase PCR takes place in three 
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important steps i.e., denaturation of double stranded RNA, reverse transcription of 
dsRNA to form the complementary DNA and amplification of cDNA. Denaturation of 
dsRNA is brought about by heating to separate the two strands. Complementary 
primers are added along with reverse transcriptase to form the cDNA. DNA 
polymerase enzyme extends the strand and synthesizes the new cDNA. The newly 
synthesized cDNA in each cycle undergoes denaturation, annealing and extension 
steps and gets amplified. 
The genotyping methods employ a semi- nested RT-PCR where the viral RNA is 
reverse transcribed and amplified in the presence of consensus primers for genes 
encoding the VP7 and VP4 proteins (79–82). DNA obtained in the first amplification 
cycle functions as a template for the second PCR which takes place in presence of 
consensus primers and genotype specific primers. The products obtained are analysed 
after agarose gel electrophoresis and depending on the size of the products on the gel, 
the genotypes are determined.  
Alternately the reverse transcription step can be carried out in presence of random 
hexamers instead of specific primers to obtain cDNA. The advantage here is that other 
enteric viruses can also be detected using specific primers for those viruses since the 
random hexamers prime any RNA present in the specimen (83). 
5.6.3. Real time reverse transcriptase PCR 
Real time PCR helps in quantitation of rotavirus particles present in the sample. It 
detects nucleic acids present in minute amounts. 
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6. REAL TIME POLYMERASE CHAIN REACTION 
Post PCR analysis and quantitation following reverse transcription PCR is by gel 
electrophoresis and analysis of the image. Real time PCR offers a platform where the 
PCR product can be measured at each cycle in real time with precision using 
fluorescent dyes/probes which emit increasing signal with increase in amplicons. The 
fluorescent reporters used usually are dsDNA binding fluorescent dyes, or PCR 
primers/probes attached with the dye molecules. The fluorescence change is measured 
by an instrument that combines thermal cycling with fluorescence scanning ability. By 
plotting fluorescence against the cycle number, the amplification plot is generated. 
The entire amplification and detection occurs in a single tube eliminating the need for 
post PCR manipulations. 
Steps involved in real time PCR 
6.1. Denaturation 
High temperatures (95°C) are used to separate the two strands of the dsDNA. The 
denaturation time can be increased based on the amount of GC content present in the 
template. 
6.2. Annealing 
This is calculated based on the melting temperature (Tm) of the primers which is 
usually 5°C below the Tm of the primer. Complementary sequences hybridize during 
this stage. 
6.3. Extension 
The activity of the polymerase enzyme is best at 70-72°C. When the amplicons are 
small, this step is combined with the annealing step using 60°C as the temperature. 
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6.4. Fluorescence detection systems 
The most commonly used fluorescence detection systems in real time PCR are the dye 
based assays and 5‟ nuclease assays.  
6.4.1. Dye based chemistry 
The commonly used DNA binding dye is SYBR Green I. It binds non specifically to 
dsDNA which exhibits little fluorescence in the unbound state. The fluorescence 
increases 1000 fold when it is bound to dsDNA. This fluorescence signal increases as 
the target gets amplified. A major drawback of these DNA binding dyes is their lack 
of specificity as they bind to any double stranded DNA.  
6.4.2. Fluorescent Primer and Probe based Chemistries  
The most common probe based chemistry is TaqMan chemistry. Taq polymerase is 
thermostable and has 5‟ exonuclease activity. In addition to the exonuclease property, 
these assays also exhibit a phenomenon called fluorescent resonance energy transfer 
(FRET). In FRET, energy from a fluorescent dye can be reduced by the presence of 
another dye in close proximity called the quencher. It employs a sequence specific, 
fluorescently labelled oligonucleotide probe called the TaqMan probe. It contains a 
fluorescent reporter at the 5‟ end and a quencher at the 3‟ end. When the probe is 
intact, FRET phenomenon is at its optimum before the PCR starts. Once the annealing 
/ extension takes over, the probe hybridizes to the target and the 5‟ exonuclease 
activity of the Taq polymerase cleaves off the reporter. The fluorescence is not 
quenched as the reporter is separated from the quencher and it increases with each 
amplification cycle. 
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6.4.2.1. Types of Taqman probes 
The two types of Taqman probes are the MGB and non-MGB probes. The non-MGB 
probes were used initially and where TAMRA® dye was used. The annealing 
temperatures of these probes had to be higher than the primers to allow cleavage to 
take place and hence the probes had to be longer than the primers.  
The MGB probes have a minor groove- binding molecule on the 3‟ end. A minor 
groove is formed in the DNA where the probe binds and this raises the melting 
temperature of the probe. Taqman MGB probes are short. Hence even a single base 
mismatch has an impact on probe binding. Hence real time PCR employing Taqman 
MGB probes are highly specific. 
 
6.5. Passive reference dye 
Use of passive reference dye in real time PCR helps in normalizing the fluorescence 
signals that are not related to the PCR cycle and provide a stable baseline.  
High specificity and high signal to noise ratio are the main advantages of using 
TaqMan probes. Detection of rotavirus using real time PCR is higher than that 
detected using reverse transcriptase PCR and the time  is half that required for 
conventional PCR. Real Time PCR when initially performed on rotavirus, amplified a 
highly conserved region in the non structural protein 3 which is 87- bp long (84).  
In addition to the need for understanding the biology of replication, there is a need for 
viral load estimation to attribute a causal relationship in patients with diarrhoea 
because some healthy individuals also can be positive for rotavirus when very 
sensitive nucleic acid detection methods are employed.  
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Figure 7. Diagrammatic representation of the steps in real-time PCR thermal 
cycling process 
 
6.6. Amplification curve 
Amplification curve in a PCR run  can be divided into three important phases. 
6.6.1. Exponential phase 
A doubling of the reaction products happen during this phase. The reaction runs at 
100% efficiency because all of the reagents are available. Hence double the  
amplicons accumulate at the end of the cycle.  
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6.6.2. Linear phase 
As the reaction progresses, the reagents get consumed whenever there is doubling of 
the amplicons. At this point, the reaction starts to slow down and there is no more 
exponential increase seen in the amplicons. 
6.6.3. Plateau phase 
The reaction stops in this phase and no more amplicons will be made. The PCR 
products may even degrade if left long enough. Each sample has its own plateau phase 
depending on the reaction kinetics of the sample. 
 
6.7. Real time PCR analysis 
                                                             
 
 
 
 
 
 
 
 
 
 
                           Figure 8. Real time PCR plot 
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6.7.1. Baseline 
It is the signal level in the initial cycles of the real time PCR where there is little or no 
change in fluorescent signal. If low level signal can be detected at this point, it is 
considered as the background „noise‟. Baseline should be determined carefully so that 
enough cycles contributing to background noise are eliminated and at the same time, 
care should be taken to see that no amplification signal is missed. 
6.7.2. Threshold 
Threshold is the level which separates background noise from relevant real 
amplification. It can be set manually or automatically. In the automatic mode, the 
machine sets it at 10 times the standard deviation of the fluorescence value of the 
baseline. 
6.7.3. Threshold cycle (Ct) 
It is the cycle number at which the fluorescent signal of the reaction crosses the 
threshold. Ct value is inversely related to the starting amount of the target.  
6.7.4. Standard curve 
A known template is serially diluted and a standard curve is constructed to determine 
the initial amount of the target template. The log of each concentration on the x-axis is 
plotted against the Ct value for that concentration. Using the standard curve, the 
performance of the reaction and the various reaction parameters can be deduced. The 
concentrations of the known template should be chosen in such a way that they 
encompass the expected concentration range of the target templates used in the real 
time PCR. 
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6.7.5. Correlation coefficient (R
2
) 
It determines how well the data fits the standard curve. It is a reflection of the linearity 
of the standard curve. 
6.7.6. Slope of the standard curve 
The slope of the log linear phase of amplification reaction is a measure of efficiency 
of the reaction. A reaction efficiency of 100% corresponds to a slope of -3.32. 
6.7.7. Efficiency 
An ideal efficiency of 100% means that the template doubles after each thermal cycle 
during exponential amplification. Length, secondary structure and GC content of the 
amplicon are the experimental factors that can influence efficiency. Using non optimal 
reagents, presence of PCR inhibitors in the reagents are a few of the reaction factors 
that contribute to altered efficiencies. A reaction efficiency between 95% and 105% is 
considered acceptable. 
6.7.8. Dynamic range 
This is the range over which an increase in starting material concentration results in a 
corresponding increase in amplification product. 
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7. TREATMENT    
 
Treatment mainly focuses on rehydration and ameliorating the effects of dehydration 
caused by diarrhea. There is no specific treatment other than fluid replacement and 
zinc. Low osmolality solutions are preferred over conventional formulations of oral 
rehydration salts (89). Since rotaviral diarrhea is also associated with vomiting, the 
extent of dehydration is much more, and oral rehydration alone may not be sufficient 
in severe cases. The child may need hospitalization and intravenous rehydration. The 
health care seeking in these developing countries is also less owing to social, 
economic and cultural constraints. Thus vaccines hold a promising future in 
restraining the mortality and morbidity due to rotavirus gastroenteritis.  
However, the effectiveness of these vaccines in the poorest regions, which contribute 
to majority of mortality, is still questionable due to the existence of other concomitant 
infections and the lack of information on the circulating and newly emerging strains in 
those geographical regions. 
Some studies showed that passive immunization using hyperimmunised bovine 
colostrum or chicken yolk immunoglobulin were protective against rotavirus diarrhea 
(86–88). Racecadotril which is an encephalinase inhibitor acts on the enteric nervous 
system mediated secretory component of rotavirus diarrhea and can be used in the 
treatment of rotavirus diarrhea (89). Oral administration of certain lactobacillus 
species in children with rotavirus diarrhea reduced the duration of watery diarrhea 
(90). Laboratory studies using recombinant monovalent antibody fragments derived 
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from llama immunized with rotavirus showed neutralizing effect on various common 
genotypes of rotavirus (91). 
 
8. ROTAVIRUS VACCINES 
Studies conducted on the natural history of rotavirus infections showed that the initial 
infections after the neonatal period were symptomatic but conferred protection on the 
subsequent infections (33,92,93). These findings provided the necessary scientific 
rationale that this immunity could be imparted using live oral vaccines. It was also 
seen that vaccines of low immunogenicity showed high efficacy in field trials. Hence 
conducting clinical trials on a large scale may be the only secure means to estimate the 
effectiveness of a vaccine (94,95). 
The use of vaccines should ideally be a component of a comprehensive strategy 
targeted to control diarrheal diseases. The other components should include 
improvement in general hygiene and sanitation, zinc supplementation, administration 
of oral rehydration solution and better management of cases (96). Efforts to 
manufacture a vaccine against rotavirus started in the1980s. In 1983,the first trial with 
a candidate oral vaccine derived from RIT4237strain, which is a bovine rotavirus 
strain was carried out. Its results showed four basic principles regarding live oral 
rotaviral vaccines. 1. They can shield children against severe diarrhea. 2. Protection 
was more against severe gastroenteritis as compared to milder episodes. 3. Animal 
strains can protect individuals from infections caused by human strains. 4. The 
antibody levels did not determine the effectiveness of the vaccine. The RIT vaccine 
developed by Vesikari did not show consistent outcome in clinical trials in developing 
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countries and was abandoned. After 15 years, the first vaccine Rotashield
TM
 (Wyeth- 
Lederle, Pearl River, NY, USA) was licensed in  the United States in August 1998. It 
was developed at the National Institute of Health and was a rhesus derived tetravalent 
reassortant vaccine (97,98). 
Nine months after administering it to well over 60000 children, it was withdrawn from 
the market because of several cases of intussusception  following its administration 
(99). The risk was assessed to be 1 in 10,000 vaccine recipients (100). Intussusception 
was seen more in the „catch-up‟ group who were older than 90 days of age. Since the 
risk of natural intussusception is lower in the first 3 months of life and hence 
subsequent vaccines targeted this age group for clinical trials. 
Two vaccines which are currently widely available are Rotarix
® 
from 
GlaxoSmithKline Biologicals, Rixenstart, Belgium and Rotateq
® 
from Merck & Co. 
Inc., West Point, PA, USA. Both are live attenuated oral vaccines. Rotarix is a 
monovalent vaccine from a G1P[8] strain isolated from a case of gastroenteritis in an 
infant which was subjected to serial passages in tissue culture for attenuation. 
RIX4414 was the resulting strain and it is propagated in Vero cell lines. It is 
administered as two doses; the first after six weeks of age and the second before 24 
weeks of age. Severe combined immune deficiency syndrome is a contra indication 
(101,102) because of the danger of prolonged shedding.These vaccines can be 
administered along with the routine childhood vaccinations.  
The pentavalent vaccine is a human- bovine reassortant vaccine. Its origins are from 
human and bovine parent strains where five reassortants express either one of the four 
VP7 proteins (G1, G2, G3 or G4) belonging to human strains and P7[5] from the 
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parent bovine strain or P1A[8] which is a VP4 protein from a human strain and and 
G6 protein from the parent bovine strain. All the five reassortants are finally 
propagated in Vero cell lines employing standard techniques. Three doses of 
pentavalent vaccine are given at 2,4 and 6 months of age. During the first week after 
administration of  any of the rotavirus vaccines, the child has to be carefully watched 
for any episodes of severe crying, vomiting, irritability, blood in stools, which may be 
indicative of intussusception.  
8.1. EFFICACY OF THE VACCINES 
Rotarix and Rotateq vaccines showed an efficacy of 80% – 90%  against severe 
rotaviral gastroenteritis in WHO regions with  very low or low child and adult  
mortality  rates, but 40% - 60%  efficacy was seen in WHO regions with high child 
and very high adult mortality (103,104). In Asian and African countries, efficacy is 
low but there is a substantial public health impact because of the high burden of 
disease, since these countries account for almost 85% of rotaviral diarrheal deaths 
worldwide. A great diversity in existing strains, and occurrence of mixed infections 
and the ongoing reassortment between the human and animal strains  have so far not 
posed a challenge to the vaccines‟ ability to offer cross protection. 
8.2 Other vaccines 
The Lanzhou strain used was isolated from a lamb with diarrhea and was grown on 
cell lines of primary calf  kidney. It was licensed as a vaccine in China. Not much data 
is available on the safety, immunogenicity and efficacy of this vaccine (105). 
 
 
40 
 
The Rotavac vaccine is monovalent, based on the 116E strain of rotavirus which was 
recovered from asymptomatic infections in neonatal units in New Delhi. This strain 
was shown to offer protection against severe diarrhea (92). It was characterized at 
AIIMS Delhi as G9P[11] human – bovine reassortant, with VP4 of bovine origin and 
the rest of the segments of human origin (80). The vaccine completed the first two 
phases of clinical trials successfully and interim reports from the phase III trials from 
three different centres in India ie. NewDelhi, Pune and Vellore showed good results. 
This vaccine will be available at a low price if approved for licensure.  
 
9. CLINICAL SCORING OF GASTROENTERITIS 
Early vaccine studies revealed that the vaccines did not protect against all severities of 
diarrhea equally and that a vaccine should be able to protect against severe clinical 
outcome. There were no clear definitions or cut offs for measuring severity. Different 
descriptions and definitions were used in different studies to measure severity.  
To measure the vaccines‟ ability to cause a reduction in severity of diarrhea, 
numerical scores can be given to most important clinical symptoms in diarrhea.  
A 0-9 point scoring system was put forth by Hjelt et al which took four clinical 
parameters into consideration (106). They are duration of diarrhea, number of 
episodes of diarrhea in a 24 hour period, duration of vomiting and fever. Flores et al 
added degree of dehydration and treatment as additional parameters and brought forth 
a 0-14 point scoring system (107). 
Thus different vaccine trials were evaluated by a different scoring system eg. Scoring 
system devised by Duffy et al 1986, Gotheforset al 1989, Clark etal 1988, Vesikariet 
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al 1984 (4,108–110). Two of these scoring systems, the Clark scoring system and the 
Vesikari scoring system have been routinely used in vaccine trials. The Clark scoring 
system does not assess the degree of dehydration. There have been discrepancies 
between the various scoring systems  in assessing the clinical severity even when they 
were compared in the same clinical trial (111). One of the important components to be 
assessed when comparing the different scoring systems is their ability to detect severe 
diarrhea. Vesikari scoring system is considered the best scoring system for 
gastroenteritis in rotaviral clinical trials (112) with relatively standardised endpoints. 
 
9.1 Parameters and Scoring in the Vesikari scoring system 
It is a 0-20 point numerical scoring system based on the clinical features with which 
the child presents to the health care facility and the distribution of clinical history into 
the the respective categories of the scoring system (4). According to theVesikari 
scoring system, a score below 5 is considered „mild‟, between 6 to 10 is „moderate‟, 
between 11- 15 is „severe‟ and  above 16 is considered  „very severe‟ gastroenteritis. 
In children below 6 months of age, any alteration in number or stool consistency 
which the mother felt was diarrhea was considered diarrhea. Atleast one day of 
diarrhea preceeded and followed by two or more diarrhea free days was considered an 
episode of diarrhea (113). The episode ends on the day the child starts to pass normal 
stools. 
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Components of the scoring system 
10.1.1. Diarrhea 
The highest number of times the child passes stools is captured in the record and 
scored accordingly.  
10.1.2. Vomiting 
The highest number of times the child vomits in a 24-hour period is captured and 
scored accordingly.  
10.1.3. Temperature 
The highest temperature in a 24-hour period is taken. Rectal temperature is ideal. 
Axillary, oral or otic temperatures can also be taken. 
10.1.4. Duration of diarrhea 
The total number of days from the beginning of the diarrheal episode till the child 
turns symptom free. 
10.1.5. Duration of Vomiting 
The total number of days from the beginning of vomiting episodes till the child is 
emesis free. This is calculated in a manner similar to diarrhea duration. 
10.1.6. Dehydration 
The degree of dehydration is calculated using four parameters. They are, appearance 
of the eyes, general condition of the child (irritable, restless, lethargic, unconscious), 
thirst level and skin turgor. This can be done per the physician‟s assessment or using 
the WHO Integrated Management of Childhood Illnesses dehydration treatment 
criteria..  
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10.1.7. Treatment 
Hospitalization is more of concern than rehydration according to the scoring system 
because in some of the developing countries IV rehydration may be administered even 
without admitting the child to the hospital. Hence hospitalization is given a score of 2 
and rehydration (IV or oral rehydration) is given a score of 1.  
 
Table 5. Vesikari scoring system 
 
 0 points 1 point 2 points 3 points 
Diarrhea duration (days) 0 1 – 4  5 ≥ 6 
Maximal number of 
diarrheal stools per 24-h 
period 
0 1 – 3 4 – 5 ≥ 6 
Vomiting duration (days) 0 1 2 ≥ 3 
Maximal number of 
vomiting episodes per 24-
h period 
0 1 2 – 4 ≥ 5 
Maximal recorded 
temperature, (fever) 
Celsius scale 
<37 37.1 - 38.4 38.5 - 38.9 ≥ 39.0 
Degree of dehydration None  Some Severe 
Treatment None Rehydration Hospitalization  
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MATERIALS AND METHODS 
 
Study design 
 This was an observational study conducted at the Wellcome Trust Research 
Laboratory, Christian Medical College, Vellore in collaboration with the different 
units of Child Health Department. The institution is a 2400 bedded tertiary care centre 
with several paediatric wards that offer both general and specialist care to children. 
The institution also runs a separate emergency department for paediatric age group 
patients. The Wellcome Trust Laboratory is involved in studies on paediatric 
diarrhoea. It is the World Health Organisation Rotavirus Reference Laboratory for the 
South East Asian Region. 
  
Inclusion criteria 
Children below 5 years of age presenting with diarrhea to the Paediatrics department. 
 
Study duration 
The study was conducted over a period of 15 months from June 2012 to August 2013 
after obtaining approval from the Institutional Review Board and Ethics Committee. 
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Study samples 
Faecal specimens from children below 5 years of age were collected. A total of 150 
positive samples was aimed for with 50 samples in each of the three clinical 
categories, i.e., mild, moderate and severe. The sample size was calculated based on 
the feasibility of the study as the outcome was not predictable. Vesikari scoring 
system was employed to score severity of diarrhea in the study children. The majority 
of the samples were taken from the studies being conducted on rotavirus strain 
surveillance at the Wellcome Trust Research Laboratory. The rest of the samples were 
collected from the in-patient and out-patient wards and the emergency department of 
Child Health after obtaining the necessary consent from the parent/ guardian. 
Collection, Transport and Storage 
Faecal specimens which are collected as part of the Indian National Rotavirus Strain 
Surveillance program are screened for at the Wellcome Trust Research Laboratory 
routinely for rotavirus using the Rotaclone ELISA kit to detect VP6. These samples 
are collected by the parent or nurse, kept in the ward refrigerator and handed over to 
the study staff for transport to the laboratory. Parents were informed about the study, 
and after the consent was obtained, a clinical assessment was performed by a nurse 
using the components on the modified Vesikari Scoring system and the appropriate 
score was attributed to that particular sample. Passage of three or more loose or 
watery stools in a 24 hour period was considered diarrhea. 
If the sample was received in the laboratory too late for the ELISA to be performed on 
the same day, the specimens were stored at 4°C for ELISA to be done on the 
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subsequent day. All the specimens were aliquoted into vials and stored at -70°C for 
further characterization. Rotavirus positive stool samples after ELISA were taken for 
the current study and were subjected to RNA extraction, cDNA conversion and real-
time polymerase chain reaction. 
Since most of the samples thus obtained were from the in-patient wards and children 
with moderate to severe diarrhea usually got admitted, children from the out-patient 
clinic and emergeny department who would not need admission to the wards were 
also recruited into the study. Consent was obtained by the field nurse/staff or the 
principal investigator from the parent/ guardian after providing information about the 
study. The process employed was similar to that of the samples collected for strain 
surveillance. 
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STUDY ALGORITHM 
 
 
 
 
Specimens transported to the laboratory
Test specimens by Rotaclone EIA
Positive
Aliquot and store at -70 C, discard negatives
Thaw when needed for RNA extraction and reverse transcription
Real time PCR using Taqman probes
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ENZYMEIMMUNOASSAY FOR ANTIGEN DETECTION FROM FECAL 
SPECIMENS 
 
 
 
 
 
 
 
                                  Figure 9. Rotaclone ELISA kit 
Premier Rotaclone
® 
kit was used for antigen detection in stool fecal specimens by 
ELISA. The microtitre wells that are provided in the kit are coated with murine 
monoclonal antibody against the protein encoded by the 6
th
rotaviral gene (VP6). The 
same monoclonal antibody conjugated to horse radish peroxidise is used in the 
detector system. The results of the test were read using a spectrophotometer at 450nm. 
The samples were considered positive when the A450 was > 0.150. The procedure 
described in the Standard Operating Procedure and kit manual was strictly adhered to 
while performing the ELISA. Personal protective equipment and a biological safety 
cabinet were used for all sample handling.A 10% faecal suspension made using the 
diluent provided in the kit was used for EIA (see Appendix for details).  
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RNA EXTRACTION BY QIAGEN KIT METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
QIA amp Viral RNA Mini Kit is away to extract and purify viral RNA for  use in 
amplification techniques. The kit uses silica gel based membranes which ensure 
recovery of pure and intact RNA without the use of any phenol or chloroform 
extraction or alcohol precipitation which may interfere with PCR. The silica gel based 
membrane has selective binding capacity and its combination with microspin helps in 
extraction from multiple samples at a time. The sample is first lysed under denaturing 
Pure RNA 
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conditions. This inactivates the RNases and ensures recovery of intact RNA. Different 
buffers are added to provide optimum binding of RNA to the QIAamp membrane of 
the spin column provided with the kit. Contaminants are washed away using two 
different wash buffers. RNA of high quality is eluted using RNase free buffer. This 
can be converted to cDNA or stored at appropriate temperatures. 
 
REVERSE TRANSCRIPTION 
The RNA that was extracted using the Qiagen kit extraction method was converted to 
cDNA. This was carried out in the presence of  random primers  and a reverse 
transcriptase enzyme derived from Moloney Murine leukemia virus (Invitrogen, Life 
Technologies, Carlsbad, CA). 
The procedure for RNA extraction and reverse transcription are in the appendix. 
 
ROTAVIRUS REALTIME PCR USING TaqMAN PROBES 
In real-time PCR, DNA is amplified and detected using fluorescent chemistry. Dual 
probes which are short oligos labelled with a fluorescent reporting dye at the 5‟end 
and a fluorescence quencher at the 3‟ end are used. Both the reporter dye and the 
quencher are in close proximity because of the size of the probes which are only 15 – 
25 base pairs in length. Hence no or very little fluorescence is detected. Taq DNA 
polymerase starts to extend the DNA strand from each primer during the cycling 
process. The polymerase also has exonuclease activity and this results in cleavage of 
the probe as the polymerase extends the strand downstream. The probe is degraded, 
thus separating the reporter dye from the quencher.  
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With every additional cycle in amplification, there is an increase in fluorescence 
emitted due to repeated cleavage of the probe. This helps monitor DNA amplification 
in real time and avoids post amplification procedures like gel electrophoresis. This 
also reduces the chances for cross contamination. It is a highly sensitive and specific 
method of detection of double stranded DNA and enables quantitation of specific 
pathogen levels. A 379-bp region from nucleotides 747 to 1126, which codes for aa 
241 to 367 of the VP6 gene is amplified using the VP-F and VP6-R primers (114).  
 
Figure 11. Standard curve  
 
Figure 12. Amplification plot of the standard dilutions  
 
R
N
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Interpretation of results 
1. The measurement of rotavirus specific cDNA was calculated using absolute 
quantitation by normalizing the Ct values with that of the internal plasmid control. 
2. The threshold was determined automatically in the exponential phase which reflected 
the highest amplification rate. 
3. For the crossing points resulting from the amplification curves, the threshold indicated 
the relation between the cycle number and the log concentration of cDNA. 
4. By linear regression of these data, a standard curve was constructed which helped in 
the extrapolation of concentration of cDNA present in the samples as copy numbers. 
5. The raw fluorescence data from the reporter dye in every well was plotted by the 
software. This was analysed to create a critical threshold and use this value to provide 
any Ct values. 
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Statistical Methods 
The median Ct values and the median viral load (as copy numbers) values were 
calculated across the mild, moderate and severe categories. They were compared 
against the clinical category obtained after applying the modified Vesikari scoring 
system using the non parametric Kruskal Wallis test. 
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RESULTS  
A total of 124 fecal specimens from children <5 years of age satisfying the inclusion 
criteria were included in the study. Information regarding the number of days of 
diarrhea, frequency of diarrhea in a 24 hour period, number of days of vomiting and 
its frequency, dehydration, temperature and treatment received by the child  were 
captured on the case report forms of each child. In addition to this, information about 
other concomitant infections, the diagnoses made and  the treatment given was also 
captured. Information on time taken for recovery from diarrhea was obtained from all 
the children admitted to inpatient wards.  
The study algorithm was followed and only samples which were positive by enzyme 
immunoassay (Rotaclone) were included. RNA extraction, reverse transcription and 
real-time PCR were performed on these 124 samples. Though 150 samples with 50 
from each category respectively were aimed for, in the stipulated period only 124 
samples could be obtained and analysed. The corresponding Vesikari score categories 
were 22„mild‟, 62„moderate‟ and  40 „severe‟. After real time PCR was performed, 
two samples from „mild‟ category had to be left out of analysis because there was no 
amplification seen and hence the final number of samples analysed were 122. 
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Demographic data 
Twenty nine samples were obtained from children who were brought to the paediatric 
out-patient and emergency departments and 63 samples were from children admitted 
to the inpatient wards. The above two sets of samples were collected as part of the 
National Rotavirus Strain Surveillance Program from children < 5 years of age. 
Another 32 samples were taken from a community based study in children with 
rotavirus diarrhea. Children recruited into this study belonged to an urban slum 
setting. They were brought by the mothers  to the study clinic established in that area 
by the Wellcome Trust Laboratory. The samples were all collected from symptomatic 
children under 5 years of age. 
16.30%
50.80%
32.70%
0
Percentage of children in each category
mild
moderate
severe
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The mean age in children from the hospital based samples was 13.8 months (SD 9.23) 
and from the community samples was 7.75 months (SD 1.86). The overall mean age 
of the children was 12.08 months (SD 7.96). Children from the community are of 
younger age group when compared to the children attending the main hospital. 
Gender distribution 
 
73.70%
26.20%
Sample distribution
Hospital based
community study
65%
34%
Gender distribution in 
hospital based samples
male
female
71.80%
28%
Gender distribution in 
community based samples
Male
Female
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Two thirds of the children enrolled into the study are males and the remaining one 
third are female children. This ratio is maintained in the hospital based samples 
whereas it is  more in the community based samples.   
 
Age distribution 
 
The age groups ranged from 2 months to 46 months. The majority of the children were 
older than 6 months of age. 
 
Other Clinical details  
Of the 32 samples collected from the community, 15 children (44%) presented with 
upper respiratory tract infection and one child had chicken pox. All the children were 
managed conservatively at home with oral rehydration solution for diarrhea. None of 
them received intravenous fluids.  
The most common medications prescribed to children attending the hospital out-
26%
46%
23%
5.70% 2.40%
Percentages of children in different age groups
<6 months
7 - 12 months
13 - 24 months
25 - 36 months
>36 months
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patient department was zinc sulphate suspension and oral rehydration salts. Among 
the children admitted to the inpatient paediatric wards, 3 children presented with 
sepsis of which one child was admitted to the intensive care unit. One child had 
urinary tract infection, one had dengue and another child presented with 
hypoglycaemia. Three fourths (74.6%) of the children admitted to the in- patient 
wards received intravenous fluids followed by supervised oral rehydration therapy. 
The other one fourth (24.7%) of hospitalised children received only supervised oral 
rehydration treatment while monitoring for signs of worsening dehydration.  All the 
children recruited into the study recovered completely from diarrhea.  
Data pertaining to the Vesikari scores  
Data regarding the scores for each component of the Vesikari scoring was collected 
from the case report forms and entered into excel sheet. The mean and median 
Vesikari scores were calculated. Vesikari scores ranged from 3 to 15.  
 
Table 6. Mean and median Vesikari scores in the different categories 
Category Vesikari score Mean (SD) Median 
Mild 4.71 (SD 0.64) 5 
Moderate 7.91 (SD 1.34) 8 
Severe 12.65 (SD 1.31) 13 
 
The mean and median Vesikari scores in the samples collected from the community 
and hospital were 8.43 (SD 2.97), 8 and 9.13 (SD 3.1), 9 respectively.  
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More than half of the children presented with vomiting along with diarrhea and a third 
of the children presented with temperature above 37ºC. 
Almost all the children (except four) received treatment either in the form of oral 
rehydration salts or intravenous fluids, with 39.3% receiving intravenous fluids 
followed by supervised oral rehydration. The mean and median duration at recovery in 
hospitalised children are 2.1 (SD 1.01) and 3 days respectively.   
Crossing points (Ct values) which were obtained in the real time PCR runs were used 
to calculate the viral load. Ct is a direct correlate of viral load and hence these values 
were plotted against the various parameters to study the possible associations.  
The crossing points ranged between 13.8 and 38.9. There was no association between 
the crossing points and the age even after adjusting for the site of recruitment of 
children (hospital or community, p value 0.09). There was no significant difference in 
crossing points between the community samples and hospital samples. 
86%
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Scoring of the individual components of the Vesikari scoring system 
 
1. Duration of diarrhea 
 
Majority of the children presented with diarrhea lasting for 1 to 4 days 
 
Table7. Median and mean Ct values with confidence intervals across the 
individual scores of ‘duration of diarrhea’. 
Duration score Median Ct Mean Ct 95% confidence 
Intervals 
1 29 29.3 28.46 – 30.15 
2 27.8 27.5 23.3 – 31.6 
3 28 27.43 23.15 – 31.7 
 
The median duration of diarrhea at the time of presentation to the hospital was 1 to 4 
days and it remained the same across all the age groups. Applying the Kruskal Wallis 
86%
8.20%
5.70%
Percentage of children across individual scores for 
diarrhea duration
Diarrhea 1-4 days
5 days
≥ 6 days
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test, there was no significant association found between number of episodes of 
diarrhea and median Ct values (p value 0.62). 
 
2. Number of episodes of diarrhea 
 
Majority of the children (70%) had more than six episodes of diarrhea in a 24 hour 
period. 
 
Table 8. The median and mean Ct values along with confidence intervals across 
the individual scores of ‘number of episodes of diarrhea' 
Vesikari Score 
Category 
Median Ct Mean Ct 95% Confidence 
Intervals 
1 32 32.06 29.78 – 35.13 
2 28 27.02 24.61 – 29.22 
3 28 29.14 28.28 – 29.99 
 
0.00% 10.80%
19.60%
69.60%
Percentage of children across the scores for episodes of 
diarrhea in a 24 hour period
No diarrhea
1-3 episodes
4-5 episodes
≥ 6 episodes
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Applying the Kruskal Wallis test, there was a significant association observed 
between the number of episodes of diarrhea and the median Ct values (p value 0.031). 
 
3. Duration of vomiting 
 
More than 60 percent of children presented with vomiting along with diarrhea and 
55%  had vomiting lasting for 1 to 2 days before they were brought to the health care 
facility. 
Table 9. Median and mean Ct values with confidence intervals across the 
individual scores for ‘duration of vomiting’ 
Vesikari score for 
duration 
Median  Mean 95% Confidence 
Interval 
0 28 28.8 27.3 – 30.4 
1 29 29.3 27.6 – 31 
2 28.5 28.8 27.5 – 30.1 
3 30 29.6 27.5 – 31.7 
38.50%
27.80%
27%
6.50%
Percentage of children across the scores for vomiting duration
No vomiting
1 day duration
2 days
≥ 3 days
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Applying the Kruskal Wallis test, there was no association observed between the 
duration of vomiting and the median Ct values (p value 0.94). 
 
4. Number of episodes of vomiting in a 24 hour period 
 
Majority of the children presented with vomiting along with diarrhea. 
 
Table10. Median and mean Ct values with confidence intervals across the 
individual scores for ‘number of episodes of vomiting in a 24 hour period’ 
Vomiting episodes 
score 
Median Ct Mean Ct 95% Confidence 
Interval 
0 28 28.8 27.3 – 30.4 
1 29 29.8 27.7 – 31.9 
2 29 29.04 27.4 – 30.6 
3 29 28.72 27.2 – 30.19 
 
38.50%
18%
20.40%
22.90%
Percentage of children across the scores for 'number of 
episodes of vomiting in 24 hour period
No vomiting
1 episode
2-4 episodes
≥ 5 episodes
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Applying the Kruskal Wallis test, there was no association observed between the 
number of episodes of vomiting in a 24 hour period and the median Ct values (p value 
0.48). 
 
5. Temperature 
 
About 33 percent of the children presented with temperature above 37ºC.  
 
Table 11. Median and mean Ct values with confidence intervals across the 
individual scores for ‘temperature’ 
Temperature 
score 
Median Ct Mean Ct 95% 
Confidence 
Interval 
0 28.5 29.1 28.1 – 30.1 
1 28 28.6 27.1 – 30.2 
2 26 28 23.2 - 32.7 
3 24 24  
67.20%
27.8
4
0.8
Percentage of children across the scores for 'temperature' 
<37ºC
37.1-38.4ºC
38.5-38.9ºC
≥39ºC
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Applying the Kruskal Wallis test, there was no association observed between the 
temperature recorded and the median Ct values (p value 0.5) 
 
6. Degree of dehydration 
 
 
About half the number of children recruited presented with dehydration 
 
Table 12. Median and mean Ct values with confidence intervals across the 
individual scores for ‘degree of dehydration’ 
Dehydration score Median Ct Mean Ct Confidence Interval 
0 28 29.2 28 – 30.3 
2 28 28.7 27.5 – 29.9 
3 27 27.2 24.8 – 29.5 
48.30%
47.50%
4%
Percentage of children across the scores for dehydration
No dehydration
some 
dehydration 
severe 
dehydration
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Applying the Kruskal Wallis test, there was no significant association observed 
between the degree of dehydration and median Ct values (p value 0.57). 
 
7. Treatment 
 
3% of the children were reassured and sent back without any treatment (score 0). A 
majority of children (nearly 60%) received received oral rehydration therapy.  
 
Table 13. Median and mean Ct values with confidence intervals across the 
individual scores for ‘Treatment’ component  
Treatment score Median Ct Mean Ct 95% Confidence 
Interval 
0 32.1 32.17 27.8 – 36.4 
1 28 28.9 27.8 – 29.9 
2 29 28.7 27.4 – 30.1 
 
3%
57.30%
39.30%
Pecentage of children across the scores for treatment
No treatment
Rehydration
Hospitalization
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Applying the Kruskal Wallis test, there was no association observed between the 
treatment administered and the median Ct values (p value 0.73). 
 
Real time PCR runs 
The samples were divided into five batches and real time PCR was performed over 
five different runs. The viral load was assessed in terms of crossing point (Ct) which is 
the real time PCR cycle number where fluorescence crossed the threshold. 
Statistical analysis 
All the information was entered in Excel spread sheets. Statistical analysis was done 
using SPSS version 17. Descriptive statistics like percentages, median, interquartile 
range and frequencies were calculated. Kruskal Wallis test was used to study the 
correlation between Ct values and severity on the Vesikari scoring system and also to 
study the correlation between the crossing points and the different parameters of 
Vesikari scoring system. Two of the 124 samples had undetermined crossing points 
and were excluded from analysis. 
Validity of the assay 
The negative control and „no template‟ control included with each batch had Ct values 
greater than 38.The positive control included with each batch had a Ct value within 2 
cycles of the previous run and the Ct values ranged from 22 to 26. R
2
 value obtained 
using the standards was > 0.9. Efficiency obtained using the standards in all the runs 
varied between 96% -98%. 
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Table 14.Validity of the Real time PCR runs 
 
Real time PCR 
batch 
Efficiency Slope R
2
 
1 95.92 -3.4 0.99 
2 96.45 -3.4 0.95 
3 97.1 -3.3 0.99 
4 97.1 -3.3 0.99 
5 98.04 -3.4 0.95 
 
Reproducibility of the assay 
A control VP6 plasmid was included with each PCR run and the crossing points of 
each dilution of the tenfold dilutions of the plasmid were similar across all the 5 runs. 
The plasmid dilutions and cDNA of each sample were assessed in duplicates, 
The crossing points (Ct) of the samples ranged between 13.8 and 38.9 
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Figure 13 
Serial dilutions of standard VP6 plasmid dilutions across the five real time PCR 
runs 
 
Table15. Median Ct values in the different categories 
Category Median Ct Inter quartile range 
Mild 32 29.5– 36.5 
Moderate 28 26 - 31.5 
Severe 29 27 – 31 
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Though the median Ct values of the samples in mild category were higher than those 
in the moderate and severe categories, there is little gradation observed between the 
moderate and severe categories.  
 
Figure 14. Box plot representing the median Ct in the different categories 
 
The median Ct value is lowest in the „moderate‟ category which implies a high viral 
load when compared to the mild and severe categories, but the linear regression shows 
no correlation between severity of gastroenteritis and virus excretion (p=0.16) .  
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Figure 15. Scatter plot of Vesikari scores with Crossing points
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DISCUSSION 
 
Diarrhea is the second leading cause of childhood mortality and rotaviruses are 
responsible for more than one third of these cases (2). The widespread use of 
molecular biology based techniques, are contributing to better understanding of the 
epidemiology of rotaviruses. Studies conducted so far on circulating genotypes 
convey that more than a single genotype exist in a particular geographical region and 
there are also periodic fluctuations in the circulating strains with the emergence of 
unusual strains intermittently. Environmental contamination with faeces and living 
conditions where the domestic areas are  in close proximity to animals is not an 
uncommon feature in developing countries. The possible explanation for the constant 
emergence of new genotypes is the segmented nature of the genome and the 
reassortment taking place between human and animal strains.  
The virus replicates in the gut and hence measurement of viral load in stool samples is 
a marker of its replication. Studies have shown a correlation between severity of 
diarrhea and viral load in faecal samples and also antigenemia in serum. Real time 
polymerase chain reaction helps in quantitation of viral load and its use in rotavirus 
studies enabled the study of the shedding patterns and associations with various 
pathophysiological aspects of rotavirus diarrhea. The current study was intended to 
study the correlation between severity of diarrhea and viral load. The study employed 
the Vesikari scoring system which is the best-known and the most frequently used 
scoring system in assessing severity of diarrhea measuring valid end points with 
minimal inter individual variation (115). 
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Faeces samples from children with gastroenteritis positive by Rotaclone EIA, had 
RNA extracted and reverse transcription followed by real time PCR was performed. 
The samples were broadly divided into hospital based samples which were collected 
from children attending the out-patient and emergency department and admitted to 
paediatric wards and community based samples collected from children attending the 
community clinic in a urban slum area of Vellore. The mean age of all the children is 
12 months (SD 7.96). In this study rotavirus affected majority of the children between 
7 to 14 months (IQR 7 – 14). This age group corresponds to that period when the 
passively acquired maternal antibody levels  in the child starts to wane.  
Vesikari scores ranged from 3 to 15. The difference in the mean Vesikari scores 
between hospital based samples (8.4 and SD 2.97) and community based samples 
(9.13 and SD 2.97) was not statistically significant. The majority of the samples had 
Vesikari scores between 6 and 12 (IQR 6 – 12) implying most of the samples had 
moderate diarrhea as opposed to mild and severe categories.  
Crossing points in real time PCR, being a direct correlate of viral load, were analysed 
with the components of the Vesikari scoring system. There was no correlation 
observed between the severity of diarrhea and the rotavirus load. However, when the 
individual components of the Vesikari score were analysed for any association with 
the viral load, there was a significant negative correlation seen between the number of 
episodes of diarrhea in a 24 hour period and crossing points on the real time PCR 
indicating that the greater the number of diarrheal episodes the greater is the viral load  
(p value 0.031). This is in agreement with findings from  a previous study conducted 
on rotavirus quantitation using real time PCR where there was a significant correlation 
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between the number of episodes of diarrhea and viral load (6). However, the same 
study showed significant association between severity of diarrhea and viral load. The 
current study did not reveal any significant associations between the other individual 
components of the scoring system and the viral load. The incubation period in 
rotavirus infection is 48 hours and viral excretion is expected to be high in the initial 
days of diarrhea. There was no association between duration of diarrhea and viral load 
probably because of unavoidable delays in bringing the children to health care facility. 
The scoring on most of the hospital based samples including the in-patient samples 
was mostly carried out in the busy Paediatric emergency department. Dehydration 
which is more commonly seen in rotavirus diarrhea is prone to be scored subjectively. 
The symptoms may worsen if adequate rehydration measures are not taken 
immediately and this increase in severity may not be directly related to increase in 
viral load. Modifications in the scoring system with reference to degree of dehydration 
have been introduced in some studies to ensure wider acceptance (115). 
 
LIMITATIONS OF THE STUDY 
Limitations of the study include lack of testing for other aetiology of gastroenteritis 
and lack of controls with asymptomatic infection. Though care was taken to ensure 
that cold chain was maintained,  the time interval which elapsed between collection of 
stool specimen from the child till it was transported to the laboratory was not 
recorded. Its bearing on viral load estimation cannot be completely ignored. 
Genotyping of rotavirus was beyond the scope of the study. Certain genotypes are 
associated with more severe diarrhea whereas others are asymptomatic in 
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presentation. On the other hand, the same genotype may exhibit different clinical 
presentations in different geographic locations (57,116). 
A previous study on the protective effect of natural rotavirus infection in an Indian 
birth cohort showed that more than half the children were infected by the age of six 
months (59). Almost 90% of the children acquire antibodies against rotavirus by the 
age of 5 years, and prior infections confer some degree of protection from subsequent 
infections (59,92). The level of already existing antibodies may also contribute to 
mismatch between severity and viral load. 
A small representative amount of 0.2gm of the stool sample was processed. Measuring 
the total amount of stool passed by the child each day would lead to more accurate 
quantitation, since both frequency and volume of stool in gastroenteritis may reflect 
gut damage and virus replication.  
The Vesikari scoring system is widely used, but conclusions on viral load can be 
drawn only if strict adherence to measuring the individual parameters of the scoring 
system is followed while taking into consideration other factors including existing 
antibody levels and genotypes. 
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CONCLUSION 
In this study to quantify rotavirus load using real time PCR and correlate viral load 
with clinical severity using the Vesikari scoring system, there was no significant 
correlation studied between the severity of rotavirus gastroenteritis and the viral load.  
However, with increasing episodes of diarrhea, the viral load also increased. 
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APPENDIX 
 
ENZYME IMMUNOASSAY USING PREMIER ROTACLONE® KIT 
Materials Required 
Equipment: Microplate reader, Pipettes, Pipette tips, Refrigerator, Biological Safety 
Cabinet 
Reagents 
Premier Rotaclone
®
 
Deionized water, pyrogen free 
Bovine Rotavirus lysate – Internal Control 
Procedure 
All the reagents were thawed and brought to room temperature before testing and 
replaced at 2 – 8°C soon after use. It was ensured that the wells did not dry between 
the steps. All the kit components were labelled with the date they were opened before 
proceeding with the ELISA. 
Sample Preparation 
Using the diluent provided in the kit, a 10% fecal suspension was prepared. This could 
be used for upto 3 days when stored at 2 – 8°C without affecting the assay outcome. 
This fecal suspension was vortexed for 15 minutes at room temperature to emulsify in 
the diluent. Then it was left to stand at room temperature for the sediment to settle at 
the bottom. 
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Steps 
1. The required number of wells were set in the microtitre well holder. 
2. Two drops of diluted fecal sample, positive control, negative control (sample diluent) 
and 100 µl of bovine rotavirus (BRV) were added to the bottom of separate wells. 
3. Two drops of enzyme conjugate were added to each well. All the reagents in the wells 
were mixed by gently swirling it on the table top. 
4. After step 3, the plate was allowed to incubate at room temperature for 1 hour. 
5. The liquid in the wells was poured out and the microtitre well plate is held upside 
down and tapped vigorously against absorbent paper to ensure complete removal of 
the reagents from the wells. 
6. All the wells were filled to the brim with milliQ water, which was then poured out and 
the wells tapped vigorously against absorbent paper. 
7. This washing procedure was repeated four times. 
8. Two drops from substrate A solution were added to each well. 
9. Two drops from substrate B solution were added to these wells. 
10. The microtitre well plate with all the reagents in it was incubated at room temperature 
for 10 minutes. 
11. Two drops of stop solution were added to each well. 
12. The absorbance of each well was read at 450 nm for the Optical Density  (OD) values. 
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Data interpretation 
Validity criteria 
1. The validity of the assay was evaluated by the BRV values which was used as the 
internal control. The range had to be 0.8 -0.9. 
2. The cut off value for positive control had to be greater than 0.150. 
3. The cut off value for negative control had to be less than 0.150. 
 
Acceptance Criteria 
1. The samples were considered positive for rotavirus if the absorbance units (A450) was 
greater than 0.150. 
2. If the absorbance was less than or equal to 0.150 , the samples were considered 
negative for rotavirus. 
3. The samples had to be retested if the validity and acceptance criteria were not 
obtained. 
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RNA EXTRACTION USING QIAGEN KIT METHOD 
 
Materials  
Equipment: Pipettes, Pipette tips, Disposable gloves, Microcentrifuge tubes, Vortex 
shaker, Biological Safety Cabinet, Ultracold freezer, Centrifuge 
Reagents 
QIA amp Viral RNA Mini Spin Kit Qiagen 
Controls:  
Positive Control which is a known rotavirus positive fecal suspension 
Negative Control which is a known rotavirus negative fecal suspension  
Water control : DEPC treated water  
Procedure 
Preparation of 20% Fecal Suspension  
This is made by using Minimal Essential Medium. Fecal specimens which are ELISA 
positive were stored at -70°C. These were taken out, thawed and brought to room 
temperature. About 0.2gm or 200µl of stool was measured and taken in a 
microcentrifuge tube.  
One ml of minimal essential medium was added and vortexed for 1 minute. 
Centrifugation was carried out at 10000 rpm for 5 minutes. Faecal extracts were stored 
at -20°C to -70°C until RNA extraction 
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RNA EXTRACTION 
RNA extraction is carried out using Qiagen kit extraction method (QIAamp
® 
Viral 
RNA minikit). RNA extraction is carried out in three steps using the spin columns 
provided with the kit. These spin columns fit well into any standard microcentrifuge 
tube.  These tubes are RNase free.  
Adsorption to the QIAamp membrane 
Viral RNA is adsorbed onto silica-gel membrane during centrifugation. Salt and pH 
conditions in the lysate makes sure that proteins which inhibit the  
downstreamreactions are not retained on the QIAamp membrane. 
Removal of residual contaminants 
Two wash buffers AW1 and AW2 wash the RNA bound to the membrane and make it 
free of contaminants. 
Elution  
Buffer AVE which is RNase free water that contains 0.04% sodium azide prevents 
microbial growth and resulting RNA contamination. 
Preparation of reagents 
Addition of buffer AVE to Carrier RNA 
AVE buffer was checked for any precipitates and was made precipitate free. 
AVE buffer (310µl)was added to the vial containing lyophilised carrier  RNA. The 
needed volume of this was used (up to a maximum of 6 times) and the rest stored at 2 
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to 8°C. When needed, an appropriate volume of this AVE-carrier RNA is mixed with 
stipulated amount of AVL as per the protocol standards and used. 
Buffer AW1 
This buffer is available as a 25 ml concentrate and before using it, 19ml of absolute 
alcohol (100% ethanol) was added to it to make up to a final volume of 44ml. 
Buffer AW2 
This buffer is also available as a 13 ml concentrate and before using it, 30 ml of 
absolute alcohol is added to it to make upto a final volume of 43 ml. 
Handling of spin columns 
The following precautions were taken to overcome cross contamination in view of  the 
sensitivity of the nucleic acid amplification techniques. 
The sample was carefully pipetted and applied to the spin column without wetting the 
rim of the spin column. 
Aerosol- barrier tips were used and pipette tips were changed between the transfer 
steps. 
After each pulse vortexing step, the spin columns were spun briefly to remove drops 
accumulated towards the inside portion of the lid. 
Gloves were worn throughout the procedure and were changed everytime they got into 
contact with the sample accidentally. 
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Spin Protocol 
The spin columns were always set in the respective collection tubes and remained 
closed. Only when adding reagents, they were opened one at a time. 
After adding the necessary reagents, the spin column was closed and centrifuged. The 
filtrate obtained in the collection tube was discarded and the column was transferred 
to a new collection tube. Before starting the extraction procedures the samples and 
reagents were thawed and brought to room temperature before starting the extraction 
procedure. 
Steps 
1. 560 µl of the already prepared AVL containing carrier RNA was pipetted into a 
microcentrifuge tube.  
2. 140 µl of the fecal extract supernatant was added to it. They were mixed by pulse 
vortexing for 15 sec . 
3. After step 2, incubation was carried out at room temperature (15-25C) for 10 minutes. 
Viral particles lyse completely in this duration. AVL also inactivates RNases and 
other infectious agents. 
4. Brief centrifugation was carried out to remove any droplets that accumulated on the 
underside of the lid while carrying out the previous steps. 
5. 560 µl of ethanol was taken into these centrifuge tubes and mixed by pulse-vortexing 
for 15 seconds. A brief centrifugation was carried out to remove droplets under the lid. 
Only ethanol was used in this step as other alcohols are likely to reduce the RNA 
yield. 
 
 
84 
 
6. 630 µl of sample from step 5 was pipetted carefully into a QIAamp spin column 
nested in a 2ml collection tube. Adequate measures were taken not to wet the rim of 
the spin column. This was centrifuged at 8000 rpm for 15 seconds and the spin 
column was carefully transferred into a second clean collection tube. The filtrate from 
the first collection tube was discarded. 
7. With another 630µl from the microcentrifuge tube taken into the spin column, step 6 
was repeated. 
8. 500µl of AW1 buffer was pipetted into the spin column after carefully opening the 
cap and then closed. This was centrifuged at 8000 rpm for 1 minute and the spin 
column was transferred to another clean collection tube. The filtrate collected was 
discarded appropriately. 
9. The spin column cap was carefully opened and 500µl of AW2 buffer was added to it. 
Centrifugation at full speed, i.e. 13200 rpm, was carried out for 3 minutes. 
10. The spin column was placed in a microcentrifuge tube which was not provided with 
the kit. The old collection tube with the filtrate was discarded.  
11. 60µl of AVE buffer which was at room temperature was pipetted into the spin column 
after carefully opening it. The spin column was closed and left to stand at room 
temperature for 1 minute. 
12. The microcentrifuge tube along with the column was centrifuged at 8000rpm for 1 
minute. This is enough to elute atleast 90% of RNA present in the spin column. 
13. 40 µl of this eluted RNA was used for reverse transcription and conversion to cDNA 
whereas the rest was stored at -70°C. 
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REAL TIME PCR 
Procedure 
1. Preparation of plasmid standards for quantitative PCR 
2. The plasmid has 1010 copies per sample.Ten fold dilutions were made to obtain  109 to 
10
1
plasmid standards per 2µl sample for carrying out the real-time PCR. 
3. Eight of these serial dilutions containing rotavirus VP6 fragment were included with 
each run as positive control and to derive the standard curve for quantitation of the 
virus from the fecal specimen. 
4. One set of the diluted plasmids was stored as stock plasmid at -70°C 
Preparing the Real time PCR Master Mix 
1. Master mix was aliquoted before use. 
2. Working concentrations were prepared and labelled accordingly. 
3. Preparation of the Mastermix was carried out in the clean room. 
4. All the reagents were thawed first and then briefly vortexed and centrifuged. 
5. Reagents required for 1 sample of cDNA 
Taqman Mix                                                 12.5µl 
VP6- F Primer                                                2.0 µl 
VP6- R Primer                                                2.0 µl 
VP6- Probe                                                     0.125 µl 
H20                                                                 8.3 µl 
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6. 23 µl of the above reagents mix was added to 2 µl of the cDNA obtained from the 
fecal specimen. 
 
Addition of samples and controls 
1. 2µl of the sample cDNA was added to 23µl of master mix. 
2. Gloves were changed frequently and adequate care taken to avoid cross 
contamination. 
3. Once cDNA was added to the master mix, the wells were firmly fitted with caps.  
4. Samples for standard curve were included in every run for absolute quantitation. 
5. The strips after sealing with the caps underwent spinning to remove any bubbles. 
Running the Reactions 
1. ABI 7500 Fast Real Time PCR machine was used. The computer and the machine 
were switched on first. 
2. The strips with the cDNA and master mix were loaded into the real time machine. 
3. The ABI 7500 software was accessed to prepare the template. 
4. On the real time software, the wells were labelled accordingly. The standards were 
labelled „standard‟ and the samples along with a known positive and negative were 
labelled „unknown‟. A no template control was included and labelled „negative‟. 
5. The number of copies in the known dilutions were entered against the sample identity 
in the template provided. 
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6. The run method belonging to “Invitrogen Rota quantitation using VP6 probes and 
TaqMAN chemistry” was selected from the panel displayed so that the preset 
temperatures would take over automatically.  
7. After loading the strips and setting the run method, the „start run‟ button was selected 
and the program commenced. 
8. After completion of a run, the analysis tools were used to analyse the data. The 
standard curves were checked for a good slope and R
2
 value (A perfect slope would be 
-3.3 and R
2
 1). 
9. The data was analysed in Microsoft Excel 2010. 
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Information to the Participant 
 
Rotavirus is responsible for a majority of diarrhea related deaths in children below 5 years. 1 in 
every 250 children die of diarrhea with this virus every year. Hence control measures are of 
great need. Our country is trying to make vaccinations to suit our population and at the same 
time are cost effective. Children presenting with diarrhea may have mild to very severe clinical 
symptoms. This study is being done to see the amount of virus passed out in the stools of 
children with diarrhea presenting with varying severity of symptoms. This can help us in the 
long run to evaluate the upcoming vaccines in their ability to control this rotaviral diarrhea. 
You are being requested to participate in the above mentioned study as it will help us develop a 
good tool to measure severity. 
What will you have to do? 
If you wish to take part in the study, you will have to sign the consent form first and then collect 
stool sample of your child in the container provided. 
 
Will you have to pay for the tests to be done in the study? 
You will not need to pay any amount towards the tests. 
 
Can you withdraw from the study? 
You can withdraw from participating in the study at any point of the study. 
 
Will you personal details be kept confidential? 
Information is taken in terms of severity of diarrhea and no personal details are sought. 
 
For further queries please contact Dr. Susmitha (Mob No. 09944642476) 
 
 
  
CONSENT TO PARTICIPATE IN THE STUDY 
Study title: 
Quantitation of Group A Rotavirus in children with varying severity of gastroenteritis. 
  
Study Number: 
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
___________, parent/guardian of ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provided to me regarding this study and have clarified 
any doubts that I had.                                                                                                                                            [ ] 
I also understand that participation in this study is entirely voluntary and that I am free to withdraw 
permission to continue to participate at any time without affecting any treatment or  legal rights    [ ] 
I also understand that the tests done on the specimen will be done free of cost.                                     [ ] 
I understand that the child’s identity will not be revealed in any information released to third parties [ ]   
I voluntarily give my consent to let my child take part in this study                                                      [ ] 
 
Name: 
Signature: 
Date: 
 
Name of witness: 
Date: 
Case Reporting Form 
Date                                                                     Hospital number: 
Patient serial number                                                  
Address : 
 
Diagnosis by the attending physician: 
Age of the child:                              Date of birth:                                           Sex of the child: M/F 
Clinical information 
Temperature:   ____C 
Vomiting :      Yes/No       Duration :   ____ days      Max no. of episodes in 24hrs:  __ 
Diarrhea:  Yes/No    Duration:  _____ days    Max no. of episodes in 24 hrs:  ___ 
Signs of dehydration: 
Lethargy: Yes/ No                 Restless/ Irritable:  Yes/No 
Feeding well:   Yes/No         Eyes sunken:    Yes/ No 
Skin pinch: Normal (  )     slow return  (   )        Very slow return  (   ) 
Degree of dehydration:  None (   )      some(   )       Severe (   ) 
Treatment 
Supervised oral / Intravenous rehydration 
Laboratory Information 
Rotavirus identified in stool by ELISA :    Yes/ No 
 
Person Completing the form:                                                                       Signature 
Vesikari Score: 
S.No Hosp No Age Sex
Vesikari 
score Category EIA OD Viral load Ct Sample ID
 
Diarrhe
a days
No.of 
episodes 
of 
diarrhea
 vomiting 
days
no.of 
episodes of 
vomiting TemperatureDehydration Treatment AREAS
1 379430F 5 M 5 mild 2.601 20601.09 33.7 RQ 001 1 1 1 1 0 0 1 Hosp In
2 364484F 12 M 5 mild 0.579 3491.81 36.3 RQ 013 1 1 1 1 0 0 1 Hosp In
3 389329F 6 M 5 mild 1.214 67269.56 32 RQ 014 1 1 1 1 0 0 1 Hosp In
4 LBS 083 9 M 5 mild 1.306 399 36.9 LBF 435 1 1 1 1 1 0 0 Comm
5 LBS 075 9 F 3 mild 0.204 100.22 39.9 LBF 947 1 1 0 0 0 0 1 Comm
6 LBS 156 6 M 5 mild 0.518 106727.5 28.7 LBF 2077 1 2 0 0 1 0 1 Comm
7 LBS 241 7 M 5 mild 1.115 16632.39 31.3 LBF 4289 1 1 0 0 0 2 1 Comm
8 LBS 283 7 M 5 mild 0.473 344324.723 26.2 LBF 5232 1 3 0 0 0 0 1 Comm
9 LBS 003 11 M 5 mild 0.818 57108.806 32.2 LBF 6819 1 3 0 0 0 0 1 Comm
10 046246F 20 F 5 mild 0.194 3100.07 34.8 CM0221 1 3 0 0 0 0 1 Hosp In
11 294145F 3 M 5 mild 0.535 30840.5 29.8 CM0007 1 1 1 1 0 0 1 Hosp In
12 136433F 7 M 5 mild 0.328 137.22 38.4 CM0023 2 2 0 0 0 0 1 Hosp out
13 804918D 16 M 3 mild 3.262 807756 27.7 CM0023 1 1 0 0 0 0 1 Hosp in
14 852962D 14 M 5 mild 0.634 275498.5 27.9 CM0027 1 3 0 0 0 0 1 Hosp out
15 858213D 18 F 5 mild 1.723 20033.6 32.6 CM0205 1 3 0 0 0 0 1 Hosp out
16 098971F 8 M 5 mild 0.338 29494.05 31.6 CM0239 1 3 0 0 0 0 1 Hosp out
17 597502D 34 M 5 mild 0.909 976058.8 26.6 CM0289 1 3 0 0 0 0 1 Hosp out
18 046964F 3 M 4 mild 0.247 363.886 36.3 CM0423 1 3 0 0 0 0 1 Hosp out
19 032947F 10 F 4 mild 0.331 52283.2 31.2 CM0218 1 2 0 0 1 0 1 Hosp out
20 331778F 6 M 5 mild 2.071 423.947 36.8 CM0045 1 3 0 0 0 0 1 Hosp out
21 788941D 18 M 5 mild 0.164 157.694 39.7 CM0276 1 1 1 1 0 0 1 Hosp out
22 379621F 18 M 6 moderate 1.808 142779.9 27.5 RQ 007 1 1 1 1 0 0 1 Hosp out
23 384232F 16 M 6 moderate 1.323 71886 28.5 RQ 010 1 2 1 1 0 0 1 Hosp out
24 389328F 6 M 6 moderate 2.378 5572291.1 22.2 RQ 015 1 2 1 1 0 0 1 Hosp out
25 379497F 17 M 8 moderate 2.063 101727.5 28 RQ 009 1 1 1 1 1 2 1 Hosp out
26 LBS 211 6 M 6 moderate 1.469 193787.829 27.1 LBF 4473 1 3 0 0 1 0 1 Comm
27 LBS 008 11 M 6 moderate 2.095 168002.4 28 LBF 2497 1 3 0 0 1 0 1 Comm
28 LBS 308 7 M 6 moderate 0.261 2174.916 34.3 LBF 3744 1 1 0 0 0 2 1 Comm
29 LBS 054 8 F 6 moderate 2.757 134118.493 27.6 LBF 6648 1 2 1 2 0 0 0 Comm
30 LBS 187 6 F 8 moderate 3.033 28925.61 30.5 LBF 2332 1 3 1 1 1 0 1 Comm
31 LBS 059 11 F 10 moderate 3.056 406047.2 26.7 LBF 4008 1 3 2 3 0 0 1 Comm
32 LBS 217 7 M 7 moderate 0.281 279086.5 27.2 LBF 4158 1 3 0 0 0 2 1 Comm
33 LBS 257 6 M 8 moderate 1.079 87443.399 28.2 LBF 5791 2 3 0 0 0 2 1 Comm
34 LBS 329 6 F 10 moderate 0.605 389027.276 26.1 LBF 5816 1 3 1 2 0 2 1 Comm
35 LBS 024 9 M 7 moderate 1.185 1794970647 13.8 LBF 5937 2 2 0 0 0 2 1 Comm
36 LBS 094 9 F 9 moderate 0.566 20876.84 33.7 LBF 6279 1 2 1 1 1 2 1 Comm
37 LBS 301 6 M 7 moderate 0.541 56491.767 28.9 LBF 6405 1 3 0 0 0 2 1 Comm
38 LBS 269 6 M 10 moderate 2.272 137494.582 27.6 LBF 6573 1 3 1 1 1 2 1 Comm
39 LBS 084 7 M 7 moderate 2.767 104684.606 28 LBF 6810 1 3 0 0 0 2 1 Comm
40 LBS 227 7 M 8 moderate 0.528 3351629.754 22.9 LBF 7652 1 3 1 2 0 0 1 Comm
41 LBS 299 11 F 7 moderate 1.892 88727.1986 28.2 LBF 7680 1 3 0 0 0 2 1 Comm
42 LBS 216 9 M 9 moderate 0.342 55854.737 28.9 LBF 8409 1 2 1 2 0 2 1 Comm
43 389328F 6 M 7 moderate 1.514 147243.8 24.2 CM0149 2 3 0 0 1 0 1 Hosp out
44 367536F 12 M 6 moderate 1.119 30899070.8 19.7 CM0111 1 3 0 0 0 0 2 Hosp in
45 309472F 29 M 10 moderate 1.708 364302.726 26.2 CM0009 1 3 2 2 0 0 2 Hosp in
46 085396F 13 M 9 moderate 2.348 562765.25 25.5 CM0030 1 3 0 0 1 2 2 Hosp in
47 082213F 11 M 8 moderate 1.908 73435.84 31.9 CM0070 1 3 0 0 0 2 2 Hosp in
48 927039D 22 F 10 moderate 1.416 17641404.65 20.5 CM0074 1 3 1 1 0 2 2 Hosp in
49 347835F 12 F 8 moderate 1.822 59895.12 32.2 CM0076 1 3 0 0 0 2 2 Hosp in
50 170495F 8 M 8 moderate 0.498 9607.98 34.8 CM0100 1 3 2 2 0 0 0 Hosp in
51 367550F 12 M 7 moderate 2.118 298765.754 26.5 CM0114 1 2 0 0 0 2 2 Hosp in
52 374544F 28 M 8 moderate 0.78 116747.3883 24.5 CM0123 1 3 0 0 0 2 2 Hosp in
53 207201F 7 F 10 moderate 0.78 874050062.3 14.8 CM0124 3 2 0 0 1 2 2 Hosp in
54 180938F 6 M 12 moderate 0.626 1289.531 34.6 CM0130 1 3 2 2 0 2 2 Hosp out
55 189063F 8 F 8 moderate 0.701 60032.28 32.3 CM0133 1 3 0 0 0 2 2 Hosp In
56 379497F 13 M 10 moderate 0.887 18216.806 30.6 CM0134 1 3 2 2 0 0 2 Hosp In
57 001863F 18 M 10 moderate 0.244 340.18 36.5 CM0136 1 3 0 0 2 2 2 Hosp In
58 395521F 16 F 9 moderate 0.286 226662.925 26.8 CM0147 1 3 0 0 0 3 2 Hosp In
59 389329F 6 M 9 moderate 1.614 6387.42 32.1 CM0150 1 3 0 0 0 2 2 Hosp In
60 014698F 5 M 8 moderate 1.368 10074.27 31.6 CM0153 1 3 0 0 0 2 2 Hosp In
61 314159F 29 M 7 moderate 1.22 1253697.25 24.4 CM0168 1 3 0 0 1 0 2 Hosp In
62 411128F 7 M 10 moderate 1.682 179534.7 29.6 CM0180 1 2 3 2 0 0 2 Hosp In
63 054881F 15 F 9 moderate 0.465 186557.5 29.6 CM0186 1 2 2 3 0 0 1 Hosp In
64 113103F 14 F 9 moderate 1.83 3854479 23.6 CM0194 1 3 2 2 0 0 1 Hosp In
65 179904F 13 M 10 moderate 0.498 70556307.2 20.5 CM0197 1 3 2 3 0 0 1 Hosp In
66 406355F 6 F 8 moderate 0.939 28891.86 30.6 CM0204 2 3 0 0 2 0 1 Hosp In
67 259672F 8 F 8 moderate 2.585 394879.57 27.5 CM0218 1 3 0 0 0 2 2 Hosp In
68 352539F 3 F 8 moderate 3.078 174237.8 25.3 CM0231 1 3 0 0 0 2 2 Hosp In
69 244516F 9 M 7 moderate 2.647 4108985.4 23.9 CM0232 1 2 0 0 3 0 1 Hosp out
70 354842F 7 F 7 moderate 0.314 67283.73 32 CM0083 1 2 1 1 1 0 1 Hosp In
71 074615F 12 M 6 moderate 1.319 928560.6 26.9 CM0149 1 3 0 0 1 0 1 Hosp In
72 765652D 27 M 6 moderate 0.175 1058.966 34.7 CM0347 2 3 0 0 0 0 1 Hosp out
73 399797F 8 F 6 moderate 0.331 290323.52 25.00 CM0381 2 3 0 0 0 0 1 Hosp out
74 152136F 11 F 8 moderate 0.761 868091.4 27.6 CM0030 1 2 2 2 0 0 1 Hosp out
75 162180F 7 M 8 moderate 0.28 15179.92 29.60 CM0038 1 3 1 2 0 0 1 Hosp out
76 171179F 8 F 9 moderate 0.73 15093 32 CM0039 3 3 1 1 0 0 1 Hosp out
77 937094D 12 F 7 moderate 0.499 592652.4 27.6 CM0130 1 2 2 1 0 0 1 Hosp out
78 992345D 11 F 9 moderate 0.2 6807.9 34.2 CM0170 1 3 2 2 0 0 1 Hosp out
79 162155F 6 M 8 moderate 2.262 113246.50 26.6 CM0232 1 2 2 2 1 0 1 Hosp out
80 810872D 24 F 9 moderate 3.327 589665.9 26.5 CM0308 1 3 1 2 1 0 1 Hosp out
81 280282F 2 M 7 moderate 0.391 51045 31.5 CM0330 3 3 0 0 0 0 1 Hosp out
82 110480F 10 F 7 moderate 1.419 5607011.272 25.7 CM0334 1 3 1 1 0 0 1 Hosp out
83 200807F 15 M 11 severe 1.454 117567652.2 17.7 RQ 008 1 2 1 3 1 2 1 Hosp out
84 014698F 12 F 11 severe 1.031 91029421 21.5 RQ 016 1 2 1 1 0 0 1 Hosp out
85 LBS 060 12 M 13 severe 0.798 1836414.1 25.6 LBF 054 1 2 3 3 1 2 1 Comm
86 LBS 249 6 M 11 severe 0.318 66739.58 29.4 LBF 1831 3 3 1 3 1 0 0 Comm
87 LBS 321 6 M 12 severe 0.877 201699.5 28.6 LBF 4445 1 3 2 2 1 2 1 Comm
88 LBS 235 6 M 12 severe 1.166 2971795 23.2 LBF 4718 2 3 0 0 2 3 2 Comm
89 LBS 086 9 F 12 severe 1.01 57976.195 28.8 LBF 4995 1 3 2 3 0 2 1 Comm
90 LBS 195 7 M 13 severe 0.849 71936.052 28.5 LBF 5633 3 3 2 2 0 2 1 Comm
91 LBS 157 8 F 12 severe 1.386 105079.659 27.8 LBF 5979 3 3 1 1 1 2 1 Comm
92 LBS 183 6 M 14 severe 0.323 22024.809 30.2 LBF 7307 1 3 3 3 0 3 1 Comm
93 LBS 272 7 M 12 severe 0.173 316051.3844 26.4 LBF 8800 1 3 2 3 0 2 1 Comm
94 002992F 13 M 13 severe 2.432 25422.05 30 CM0002 1 3 1 3 1 2 2 Hosp in
95 835864D 21 M 15 severe 0.159 18723.6088 30.5 CM0004 2 3 3 3 0 2 2 Hosp in
96 304506F 3 M 12 severe 3.212 50715.54 29 CM0006 1 3 2 2 0 2 2 Hosp in
97 309760F 14 F 13 severe 0.883 192014.258 27.1 CM0015 1 3 2 3 0 2 2 Hosp in
98 341986F 18 F 13 severe 1.112 235272.0098 26.8 CM0059 1 3 2 1 1 3 2 Hosp in
99 347401F 19 M 12 severe 1.13 2467.023 33.4 CM0067 1 3 1 2 1 2 2 Hosp in
100 080788F 16 M 11 severe 1.767 7044.4 35.3 CM0073 1 3 1 1 1 2 2 Hosp in
101 299574F 10 M 13 severe 0.733 1453710.47 24.1 CM0081 1 1 2 3 2 2 2 Hosp in
102 119944F 10 M 13 severe 2.34 54757.63 28.9 CM0082 1 3 2 3 0 2 2 Hosp in
103 540414D 39 M 14 severe 0.697 672.8373 36.9 CM0087 1 3 2 3 1 2 2 Hosp in
104 361083F 44 F 11 severe 1.743 14029.364 30.9 CM0088 1 2 2 2 0 2 2 Hosp in
105 119098F 13 M 12 severe 1.55 1335170.527 24.3 CM0098 1 3 2 2 0 2 2 Hosp in
106 674787D 31 M 11 severe 0.457 2634721.19 23.3 CM0106 1 2 2 2 0 2 2 Hosp in
107 384257F 5 F 11 severe 0.372 102.56 38.6 CM0137 1 3 1 2 0 2 2 Hosp in
108 804789D 27 M 12 severe 2.296 22263.805 30.3 CM0146 1 3 1 3 0 2 2 Hosp in
109 252560F 6 M 14 severe 0.186 18031.3625 30.8 CM0155 1 3 2 3 1 2 2 Hosp in
110 180514F 12 M 13 severe 0.353 97576.465 28.2 CM0166 1 3 1 3 1 2 2 Hosp in
111 394177F 11 M 13 severe 0.332 47784.78 32.7 CM0167 1 2 2 3 1 2 2 Hosp in
112 394551F 11 F 12 severe 0.646 269915.2375 26.7 CM0171 1 3 3 3 0 0 2 Hosp in
113 401189F 14 F 15 severe 0.692 1733.94 33.3 CM0176 1 3 3 3 1 2 2 Hosp in
114 415231F 12 F 13 severe 0.382 28891.856 28.9 CM0199 1 3 2 2 0 3 2 Hosp in
115 417148F 17 M 13 severe 0.511 39593.162 28.5 CM0200 1 3 2 3 0 2 2 Hosp in
116 942769D 21 M 15 severe 0.712 985712 26.8 CM0207 2 3 3 3 0 2 2 Hosp in
117 170372F 9 M 13 severe 1.706 202375.2125 28.3 CM0211 1 3 2 3 0 2 2 Hosp in
118 434162D 46 M 14 severe 2.248 17235.407 32.6 CM0225 1 3 2 3 1 2 2 Hosp in
119 439091F 8 F 14 severe 0.16 637.20898 36.4 CM0227 1 3 3 3 0 2 2 Hosp in
120 992176D 7 M 11 severe 0.164 42964.98 32.6 CM0018 1 3 2 3 1 0 1 Hosp out
121 307606F 9 M 11 severe 1.115 124637.1 26 CM0287 1 3 1 3 2 0 1 Hosp out
122 367389F 11 F 15 severe 1.803 116845.68 27.8 CM0105 3 3 2 2 1 2 2 Hosp in
Hosp in - Inpatient Hosp out - Out patient Comm - Community 
